Page last updated: 2024-10-28

ifosfamide and Bone Neoplasms

ifosfamide has been researched along with Bone Neoplasms in 413 studies

Bone Neoplasms: Tumors or cancer located in bone tissue or specific BONES.

Research Excerpts

ExcerptRelevanceReference
"Lay abstract Traditional treatment for osteosarcoma (bone cancer) includes drugs that cause cell damage, such as ifosfamide and etoposide."9.41OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. ( Bautista, F; Campbell-Hewson, Q; Gaspar, N; Huang, J; Okpara, CE, 2021)
"In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum)."9.27Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. ( Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C, 2018)
"This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy."9.22Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. ( Chen, XT; Christ, AB; Hu, JS; Luminais, SN; Ma, B; Roman, D, 2022)
"Studies of baseline prognostic factors in patients with localized osteosarcoma treated without high dose methotrexate are limited."9.20Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. ( Bakhshi, S; Batra, A; Khan, SA; Nataraj, V; Rastogi, S; Sharma, MC; Vishnubhatla, S, 2015)
"Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma."9.19Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. ( Brennan, B; Craft, A; Dirksen, U; Hjorth, L; Judson, I; Juergens, H; Ladenstein, R; Le Deley, MC; Le Teuff, G; Lewis, I; Marec-Bérard, P; Michon, J; Oberlin, O; Paulussen, M; Ranft, A; van den Berg, H; Wheatley, K; Whelan, J, 2014)
"High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)."9.19Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014)
"This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens."9.17Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013)
"We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity."9.16Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. ( Alberghini, M; Bacci, G; Bertulli, R; Bisogno, G; Capanna, R; Cefalo, G; Comandone, A; Fagioli, F; Ferrari, S; Linari, A; Palmerini, E; Parafioriti, A; Picci, P; Ruggieri, P; Tamburini, A, 2012)
"Thirteen patients, median age 18 (range: 8-34), with metastatic or axial-skeletal osteosarcoma were treated with ifosfamide 2."9.12A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. ( Lewis, I; McTiernan, A; Meyer, T; Michelagnoli, MP; Whelan, JS, 2006)
"In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)."9.12Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006)
"The SFOP-OS94 randomised multi-centre trial was designed to determine whether preoperative chemotherapy regimen combining high-dose methotrexate courses and etoposide-ifosfamide could improve the proportion of good histologic response (5% viable cells) compared to a regimen based on high-dose methotrexate and doxorubicin, in children/adolescents with localised high-grade limb osteosarcoma."9.12SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. ( Brugières, L; Dupoüy, N; Entz-Werlé, N; Gentet, JC; Guinebretière, JM; Kalifa, C; Le Deley, MC; Marec-Bérard, P; Pacquement, H; Pichon, F; Schmitt, C; Tabone, MD; Vanel, D, 2007)
"This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days."9.12Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. ( Blay, JY; Hogendoorn, PC; Kirkpatrick, A; Le Cesne, A; Leahy, MG; Lorigan, P; Papai, Z; Radford, JA; Rodenhuis, S; Van Glabbeke, MM; Verweij, J, 2007)
"The combination of cisplatin, ifosfamide and epirubicin is an active, reasonably well-tolerated regimen without grade 3 or 4 cardiac toxicity in patients with nonmetastatic extremity osteosarcoma and deserves further investigation in the context of prospective phase III trials."9.12A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. ( Atalar, AC; Basaran, M; Bavbek, ES; Bilgic, B; Eralp, L; Onat, H; Ozger, H; Saglam, S; Sakar, B, 2007)
"The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis."9.11A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. ( Benjamin, RS; Champlin, R; Donato, M; Lewis, VO; Lin, PP; Papadopolous, N; Patel, SR; Raymond, AK; Seong, CM; Yasko, AW, 2004)
"Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited."9.11High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. ( Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B, 2004)
"To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS)."9.11Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. ( Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R, 2005)
"To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity."9.11Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( Alvegard, TA; Bacci, G; Bernini, G; Bertoni, F; Böhling, T; Brosjö, O; Capanna, R; Comandone, A; Del Prever, AB; Ferrari, S; Longhi, A; Mercuri, M; Müller, C; Picci, P; Ruggieri, P; Saeter, G; Smeland, S; Tienghi, A; Wiebe, T, 2005)
"The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone."9.10Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003)
"The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma."9.10Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002)
"With the intention of starting an international protocol between Italy and Scandinavia on neoadjuvant treatment of extremity osteosarcoma using the four active drugs at maximum doses (doxorubicin 75 mg/m2 pre-operatively, and 90 mg/m2 post-operatively, cisplatin 120 mg/m2, methotrexate 12 g/m2, and ifosfamide 15 g/m2), a single center (the Rizzoli institute) performed a pilot study to closely monitor toxicity, safety, and tumor necrosis."9.10High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. ( Alvegard, TA; Bacci, G; Briccoli, A; Donati, D; Ferrari, S; Forni, C; Lari, S; Longhi, A; Manfrini, M; Mercuri, M; Picci, P; Saeter, G, 2002)
"The aim of this phase II study was to determine the efficacy of high-dose ifosfamide with moderate dose etoposide in childhood osteosarcoma."9.08Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. ( Avet-Loiseau, H; Berger, C; Bernard, JL; Brunat-Mentigny, M; De Lumley, L; Demaille, MC; Gentet, JC; Kalifa, C; Pacquement, H; Pein, F; Pillon, P; Sariban, E; Schmitt, C, 1997)
"To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas."9.08High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997)
"This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions."9.08Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997)
" The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma."9.08Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. ( Brunat-Mentigny, M; Cochat, P; Dubourg, L; Hadj-Aïssa, A; Koch Nogueira, PC; Schell, M, 1998)
"Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship."9.08Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998)
"Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas."9.07An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993)
"Nine patients with osteosarcoma were treated by chemotherapy combined with caffeine and surgery."9.07Effect of chemotherapy combined with caffeine for osteosarcoma. ( Baba, H; Tomita, K; Tsuchiya, H; Ueda, Y; Yasutake, H; Yokogawa, A, 1992)
"In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)."9.06Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.91Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015)
"The efficacy of ifosfamide-based chemotherapy in the treatment of osteosarcoma has been investigated; however, results are inconsistent."8.91Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis. ( Cai, GP; Ding, GM; Fan, XL; Zhu, LL, 2015)
"To assess testicular function after standard dose ifosfamide, we evaluated 6 young adult osteosarcoma survivors (median age at diagnosis, 16."8.90Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( Diller, L; Duffey-Lind, E; Ebb, D; Grier, H; Kenney, LB; Sklar, CA, 2014)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.88Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012)
"Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma."8.86Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.86Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010)
"The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas."8.81Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001)
"Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease."8.79High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996)
"We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985."8.78Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993)
"Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings."8.02Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021)
"For Ewing sarcoma, interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide administered every 2 weeks rather than every 3 weeks has been shown to improve event-free survival in pediatric patients."7.96Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. ( Bassale, S; Davis, LE; Lim, JY; Lu, E; Ryan, CW, 2020)
"Current treatment of high-grade osteosarcoma consists of preoperative chemotherapy, typically using some combination of doxorubicin, cisplatin, ifosfamide, and/or high-dose methotrexate followed by surgical resection."7.91Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation. ( Savani, M; Skubitz, KM, 2019)
"All treatment naive consecutive patients of osteosarcoma were prospectively treated on a novel institutional regimen (named OGS-12) comprising of eight sequential doublets of the following drugs: doxorubicin, cisplatin and ifosfamide in four courses each, given in the neoadjuvant and adjuvant settings."7.85Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. ( Bajpai, J; Banavali, SD; Chandrakanth, MV; Chandrasekharan, A; Ghosh, J; Gupta, S; Khan, A; Khurana, S; Rekhi, B; Simha, V; Talreja, V; Vora, T, 2017)
"Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide)."7.83Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Gebhardt, MC; Goorin, AM; Grier, HE; Healey, JH; Krailo, MD; Lipshultz, SE; Meyers, PA; Sato, JK; Schwartz, CL; Steinherz, LJ; Teot, LA; Wexler, LH, 2016)
"The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)."7.83Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016)
"Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma."7.81Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? ( Lin, F; Shen, Z; Tang, L; Yao, Y; Yu, W, 2015)
"The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma."7.81Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015)
"In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles (PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells."7.81Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015)
"Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide."7.80Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014)
"We sought to (1) evaluate the disease-specific survival at 2 and 5 years of patients with dedifferentiated chondrosarcoma; (2) assess the prognostic variables (both patient- and treatment-related), including the use of chemotherapy with ifosfamide, that relate to survivorship; and (3) assess specific toxicities associated with ifosfamide use."7.80Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? ( Deavers, M; Harun, N; Kawaguchi, S; Lewis, VO; Lin, PP; Sun, T, 2014)
"Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma."7.80Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014)
"This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma."7.80Ifosfamide-containing regimens for treating patients with osteosarcomas. ( Dong, YG; Jiang, XM; Li, YY; Ma, YB; Xu, G, 2014)
"A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)."7.80Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014)
"To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University."7.79Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013)
"The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively."7.79Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. ( He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H, 2013)
"The objective of this study was to investigate the efficacy and toxic side effects of two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide on treating Chinese osteosarcoma patients."7.77Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. ( Dong, Y; Lin, F; Shen, Z; Sun, Y; Tang, L; Wang, Q; Yao, Y; Yu, W; Zheng, S, 2011)
"We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution."7.76Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010)
"This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II."7.76Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. ( Chen, P; Lin, F; Sun, Y; Wang, Z; Yao, Y; Zhao, H, 2010)
"In an attempt to find leads to such markers, we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide, doxorubicin, and cisplatin."7.75Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. ( Bruheim, S; Fodstad, O; Ju, J; Xi, Y, 2009)
" Flow cytometric analyses by means of annexin-V and propidium iodide double staining and immunofluorescence staining of active caspase-3 revealed that cells subjected to a lethal dose of chloroacetaldehyde displayed features characteristic of necrosis and that caspase-3 was not activated in response to chloroacetaldehyde."7.74Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. ( Fujimoto, Y; Sakurai, K; Takahashi, K; Tanaka, H, 2007)
" We report a 9-year-old boy with osteosarcoma who experienced 2 episodes of pancreatitis 1 day and 48 days after infusion of ifosfamide (IFOS), respectively."7.74Acute pancreatitis associated with ifosfamide. ( Hung, GY; Hung, MC; Lin, PC; Tien, YC; Tiu, CM, 2007)
"Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor."7.73High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005)
"Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS)."7.73Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. ( Duan, X; Jia, SF; Kleinerman, ES; Koshkina, N, 2006)
"A 16-year-old girl with a distal femur osteosarcoma became pain-free with the first treatment of methotrexate 12."7.72Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. ( Cohen, IJ, 2003)
"To determine the activity of carboplatin/ifosfamide in patients with previously untreated osteosarcoma and to estimate patient outcomes after a multiagent chemotherapy protocol that eliminated cisplatin."7.71Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. ( Fletcher, BD; Harper, J; Jenkins, JJ; Mahmoud, HH; Marina, NM; Meyer, WH; Neel, M; Pappo, AS; Parham, DM; Poquette, CA; Pratt, CB; Rao, BN, 2001)
"Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor."7.70[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998)
"This prospective study was designed to test the activity of an ifosfamide-etoposide (VP-16) regimen on poor-risk, nonmetastatic, osteogenic sarcoma."7.70Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma. ( Ben Arush, MW; Drumea, K; Haim, N; Kuten, A; Meller, I; Moses, M; Stein, ME, 1998)
"Ifosfamide is a leading drug in soft tissue sarcoma therapy."7.70Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998)
"Ifosfamide and cisplatin are active agents that are currently used in the treatment of osteosarcoma."7.70Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. ( Arndt, C; Hawkins, D; Liedtke, R; Miser, J; Morgenstern, B; Wilson, D, 1999)
"We attempted to ascertain renal, hematologic, and neurologic tolerance to ifosfamide (IFX) in pediatric patients previously treated with large single and cumulative doses of cis-Diamminedichloroplatinum-II (CDP) for osteosarcoma (OS)."7.69Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations. ( Canpolat, C; Jaffe, N; Pearson, P; Robertson, R, 1996)
" A 16-year-old girl with metastatic osteosarcoma experienced recurrent bouts of symptomatic pancreatitis 24 hours after treatment with ifosfamide administered as a single agent."7.69Acute pancreatitis after ifosfamide therapy. ( Adamson, PC; Balis, FM; Blaney, SM; Izraeli, S, 1994)
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)."7.69[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."7.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)."7.68Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993)
"To improve the accuracy of magnetic resonance imaging (MRI) in evaluating the response of osteosarcomas to preoperative chemotherapy, the authors developed a technique of mapping tumor necrosis and viability by quantitating slope values of gadolinium-DTPA (Gd-DTPA) uptake on dynamic fast low-angle shot (FLASH) images."7.68Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. ( Fairclough, DL; Fletcher, BD; Hanna, SL; Le, AH; Meyer, WH; Parham, DM, 1992)
"A 13-year-old boy with unresectable pulmonary metastatic osteosarcoma, which was refractory to high dose methotrexate, adriamycin, cisplatin and combination of bleomycin, cyclophosphamide and actinomycin D, was treated by aggressive chemotherapy including the combination of ifosfamide (1 g/m2 x day 1-4), Carboplatin (100 mg/m2 x day 1-4) and Vindesine (4 mg/m2 x day 1)."7.68[Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report]. ( Fujita, H; Ishimoto, K; Kiyokawa, N; Kyo, K; Mizuno, T; Takada, K; Yabuta, K, 1991)
"We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors."7.67A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986)
"" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle."6.80Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015)
"Patients <30 years old with Ewing sarcoma were eligible."6.80Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015)
" The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome."6.71High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ( Crews, KR; Daw, NC; Link, MP; Liu, T; Meyer, WH; Panetta, JC; Rodriguez-Galindo, C; Tan, M, 2004)
"Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s."6.52Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials. ( Lai, Z; Lin, Y; Mo, Y; Su, W; Wu, F; Wu, J; Yang, Z, 2015)
"Dose-intensive chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide is more effective, less toxic, and shorter in duration for all stages of newly diagnosed Ewing sarcoma than vincristine, ifosfamide, doxorubicin, and etoposide induction and should now be the standard of care for Ewing sarcoma."5.51Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. ( Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J, 2022)
"Lay abstract Traditional treatment for osteosarcoma (bone cancer) includes drugs that cause cell damage, such as ifosfamide and etoposide."5.41OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. ( Bautista, F; Campbell-Hewson, Q; Gaspar, N; Huang, J; Okpara, CE, 2021)
"Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments."5.37Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011)
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity."5.37High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011)
"The effect of immunotherapy with interleukin-18 (IL-18) in combination with preoperative chemotherapy on the postoperative progression of pulmonary metastasis was examined using a spontaneous pulmonary metastasis model of mouse osteosarcoma."5.35Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. ( Futani, H; Hata, M; Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamanegi, K, 2009)
"Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease."5.32VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. ( Allam, A; Bazarbashi, S; El Foudeh, M; El Hassan, I; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, M, 2004)
"In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum)."5.27Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. ( Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C, 2018)
"We examined the clinical significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on the Glutaminase 1 gene (GLS1) expression."5.27Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression. ( Li, H; Li, X; Sun, XH; Yan, XF; Zhang, SP, 2018)
"The European Organization for Research and Treatment of Cancer (EORTC) 62012 study was a Phase III trial of doxorubicin versus doxorubicin-ifosfamide chemotherapy in 455 patients with advanced soft tissue sarcoma (STS)."5.24Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. ( Collin, F; Daugaard, S; Fisher, C; Gronchi, A; Grünwald, V; Hogendoorn, PCW; Judson, I; Lia, M; Litière, S; Mechtersheimer, G; Messiou, C; Sciot, R; van der Graaf, W; Wardelmann, E; Young, RJ, 2017)
"This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy."5.22Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. ( Chen, XT; Christ, AB; Hu, JS; Luminais, SN; Ma, B; Roman, D, 2022)
"Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA."5.20EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. ( Anninga, J; Bernstein, M; Bielack, SS; Böhling, T; Butterfass-Bahloul, T; Calaminus, G; Capra, M; Deffenbaugh, C; Dhooge, C; Eriksson, M; Flanagan, AM; Gelderblom, H; Goorin, A; Gorlick, R; Gosheger, G; Grimer, RJ; Hall, KS; Helmke, K; Hogendoorn, PC; Hook, JM; Jovic, G; Jundt, G; Kager, L; Krailo, M; Kuehne, T; Lau, CC; Letson, GD; Marina, N; Meyer, J; Meyers, PA; Morris, C; Mottl, H; Nadel, H; Nagarajan, R; Randall, RL; Schomberg, P; Schwarz, R; Smeland, S; Sydes, MR; Teot, LA; Whelan, JS, 2015)
"Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma."5.20Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. ( Brennan, B; Brichard, B; Craft, A; Dirksen, U; Gaspar, N; Gelderblom, H; Hjorth, L; Judson, I; Juergens, H; Kruseova, J; Kühne, T; Ladenstein, RL; Le Deley, MC; Le Teuff, G; Marec-Berard, P; Paulussen, M; van den Berg, H; Wheatley, K; Whelan, J, 2015)
"Studies of baseline prognostic factors in patients with localized osteosarcoma treated without high dose methotrexate are limited."5.20Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. ( Bakhshi, S; Batra, A; Khan, SA; Nataraj, V; Rastogi, S; Sharma, MC; Vishnubhatla, S, 2015)
"Cyclophosphamide may be able to replace ifosfamide in consolidation treatment of standard-risk Ewing sarcoma."5.19Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. ( Brennan, B; Craft, A; Dirksen, U; Hjorth, L; Judson, I; Juergens, H; Ladenstein, R; Le Deley, MC; Le Teuff, G; Lewis, I; Marec-Bérard, P; Michon, J; Oberlin, O; Paulussen, M; Ranft, A; van den Berg, H; Wheatley, K; Whelan, J, 2014)
"High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)."5.19Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014)
"To improve the treatment results of patients with locally advanced osteosarcoma with large volume using neoadjuvant chemotherapy (NACT) (ifosfamide at a dose of 18 g/ml) and planning of organ-conserving surgery by evaluating the state of tumor pseudocapsule."5.17Treatment of large osteosarcoma in children: new approach. ( Golovko, TS; Gulak, LO; Kobys, VL; Konovalenko, VF; Matyushok, OF; Repinа, NV; Tarasova, TO; Zaharycheva, EV, 2013)
"This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens."5.17Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013)
"We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity."5.16Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. ( Alberghini, M; Bacci, G; Bertulli, R; Bisogno, G; Capanna, R; Cefalo, G; Comandone, A; Fagioli, F; Ferrari, S; Linari, A; Palmerini, E; Parafioriti, A; Picci, P; Ruggieri, P; Tamburini, A, 2012)
"Chemotherapy with alternating vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide cycles and primary tumor treatment with surgery and/or radiation therapy constitute the usual approach to localized Ewing sarcoma in North America."5.16Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. ( Dickman, PS; Dormans, JP; Grier, HE; Healey, JH; Krailo, MD; Marcus, K; Pawel, BR; Sailer, S; Weiss, AR; West, DC; Womer, RB, 2012)
"Patients aged ≤40 years with nonmetastatic Ewing sarcoma (ES) received vincristine (V), doxorubicin (A), cyclofosfamide (C), actinomycin (Ac), ifosfamide (I) and etoposide (E) (VACAc-IE regimen) as induction chemotherapy."5.15Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. ( Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T, 2011)
"To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma."5.13Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. ( Bernstein, ML; Betcher, D; Ferguson, WS; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, M; Healey, JH; Kleinerman, E; Krailo, MD; Link, MP; Meyers, PA; Nadel, H; Nieder, M; Schwartz, CL; Siegal, GP; Weiner, MA; Wells, RJ; Womer, RB, 2008)
"Thirteen patients, median age 18 (range: 8-34), with metastatic or axial-skeletal osteosarcoma were treated with ifosfamide 2."5.12A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. ( Lewis, I; McTiernan, A; Meyer, T; Michelagnoli, MP; Whelan, JS, 2006)
"The outcome of patients with metastatic osteosarcoma treated in two consecutive trials from 1986 to 1997 was analyzed to evaluate the efficacy of carboplatin-based multiagent chemotherapy and to identify prognostic factors."5.12Metastatic osteosarcoma. ( Billups, CA; Cain, AM; Daw, NC; Jenkins, JJ; McCarville, MB; Meyer, WH; Neel, MD; Rao, BN; Rodriguez-Galindo, C, 2006)
"In the prospective high-risk sarcoma (HIRISA) Phase II trial HIRISA1, pediatric patients with high-risk sarcomas received 3 cycles of intensive vincristine, ifosfamide, etoposide, cyclophosphamide, and doxorubicin (VACIE) before radiotherapy and/or surgery began at Week 9 with concurrent vincristine, cyclophosphamide, and doxorubicin (Week 9) and vincristine and ifosfamide (Week 12)."5.12Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience. ( Billups, CA; Cain, AM; Furman, WL; Hale, GA; Merchant, TE; Navid, F; Pappo, AS; Rao, BN; Santana, VM; Spunt, SL, 2006)
"Patients < or = 30 years with Ewing sarcoma, primitive neuroectodermal tumor or primitive sarcoma of bone were randomly assigned to receive chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin, (VACA) or with these four drugs alternating with ifosfamide and etoposide (VACA-IE)."5.12Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group. ( Bernstein, M; Chen, Z; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, M; Laurie, F; Miser, JS; Tarbell, NJ; Yock, TI, 2006)
"The SFOP-OS94 randomised multi-centre trial was designed to determine whether preoperative chemotherapy regimen combining high-dose methotrexate courses and etoposide-ifosfamide could improve the proportion of good histologic response (5% viable cells) compared to a regimen based on high-dose methotrexate and doxorubicin, in children/adolescents with localised high-grade limb osteosarcoma."5.12SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. ( Brugières, L; Dupoüy, N; Entz-Werlé, N; Gentet, JC; Guinebretière, JM; Kalifa, C; Le Deley, MC; Marec-Bérard, P; Pacquement, H; Pichon, F; Schmitt, C; Tabone, MD; Vanel, D, 2007)
"This randomized prospective multicenter phase III trial was designed to compare progression-free survival of patients with advanced soft tissue sarcoma receiving either regimen of standard doxorubicin 75 mg/m2 every 21 days, ifosfamide 9 g/m2 over 3 days continuous infusion, or ifosfamide 3 g/m2 per day in 3 hours over 3 days."5.12Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. ( Blay, JY; Hogendoorn, PC; Kirkpatrick, A; Le Cesne, A; Leahy, MG; Lorigan, P; Papai, Z; Radford, JA; Rodenhuis, S; Van Glabbeke, MM; Verweij, J, 2007)
"The combination of cisplatin, ifosfamide and epirubicin is an active, reasonably well-tolerated regimen without grade 3 or 4 cardiac toxicity in patients with nonmetastatic extremity osteosarcoma and deserves further investigation in the context of prospective phase III trials."5.12A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. ( Atalar, AC; Basaran, M; Bavbek, ES; Bilgic, B; Eralp, L; Onat, H; Ozger, H; Saglam, S; Sakar, B, 2007)
"The objective of this study was to estimate the time to treatment failure and survival rate of the three-drug combination of doxorubicin, cisplatin, and ifosfamide as primary and postoperative, adjunctive treatment for teenagers and adults with osteosarcoma (OS)."5.11Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139. ( Antman, K; Biermann, JS; Budd, GT; Lanier, KS; Lucas, DR; Meyers, FJ; Muler, J; Rankin, C; Ryan, JR; Zalupski, MM, 2004)
"The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis."5.11A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. ( Benjamin, RS; Champlin, R; Donato, M; Lewis, VO; Lin, PP; Papadopolous, N; Patel, SR; Raymond, AK; Seong, CM; Yasko, AW, 2004)
"Adding ifosfamide and etoposide to standard therapy does not improve outcomes of patients with Ewing's sarcoma or PNET of bone with metastases at diagnosis."5.11Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2004)
"Ifosfamide and doxorubicin are the most effective agents in the treatment of sarcomas, although their contributions to survival are usually limited."5.11High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. ( Akbulut, H; Buyukcelik, A; Demirkazik, A; Icli, F; Pamir, A; Utkan, G; Yalcin, B, 2004)
"To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS)."5.11Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. ( Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R, 2005)
"To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity."5.11Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( Alvegard, TA; Bacci, G; Bernini, G; Bertoni, F; Böhling, T; Brosjö, O; Capanna, R; Comandone, A; Del Prever, AB; Ferrari, S; Longhi, A; Mercuri, M; Müller, C; Picci, P; Ruggieri, P; Saeter, G; Smeland, S; Tienghi, A; Wiebe, T, 2005)
"The addition of ifosfamide and etoposide to a standard regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone."5.10Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2003)
"The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma."5.10Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002)
"With the intention of starting an international protocol between Italy and Scandinavia on neoadjuvant treatment of extremity osteosarcoma using the four active drugs at maximum doses (doxorubicin 75 mg/m2 pre-operatively, and 90 mg/m2 post-operatively, cisplatin 120 mg/m2, methotrexate 12 g/m2, and ifosfamide 15 g/m2), a single center (the Rizzoli institute) performed a pilot study to closely monitor toxicity, safety, and tumor necrosis."5.10High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. ( Alvegard, TA; Bacci, G; Briccoli, A; Donati, D; Ferrari, S; Forni, C; Lari, S; Longhi, A; Manfrini, M; Mercuri, M; Picci, P; Saeter, G, 2002)
"Twenty-four patients with soft tissue or bone sarcoma who were treated with high dose ifosfamide-based chemotherapy were enrolled in this study."5.09Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. ( Akbulut, H; Demirkazik, A; Dinçol, D; Içli, F; Onur, H; Pamir, A; Samur, M; Sencan, O; Senler, FC; Yalçin, B, 2000)
"Patients with nonmetastatic osteosarcoma of the extremity were preoperatively treated with high-dose methotrexate, cisplatin, and doxorubicin (ADM)."5.09Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. ( Bacci, G; Bertoni, F; Campanacci, M; Casadei, R; Fabbri, N; Ferrari, S; Forni, C; Longhi, A; Picci, P; Ruggieri, P; Versari, M, 2000)
"The aim of this phase II study was to determine the efficacy of high-dose ifosfamide with moderate dose etoposide in childhood osteosarcoma."5.08Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. ( Avet-Loiseau, H; Berger, C; Bernard, JL; Brunat-Mentigny, M; De Lumley, L; Demaille, MC; Gentet, JC; Kalifa, C; Pacquement, H; Pein, F; Pillon, P; Sariban, E; Schmitt, C, 1997)
"To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas."5.08High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997)
"This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions."5.08Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997)
" The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma."5.08Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. ( Brunat-Mentigny, M; Cochat, P; Dubourg, L; Hadj-Aïssa, A; Koch Nogueira, PC; Schell, M, 1998)
"Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship."5.08Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998)
"In an effort to intensify osteosarcoma therapy, systemic ifosfamide was added pre- and postoperatively to an already aggressive three-drug regimen."5.08Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. ( Bielack, SS; Bieling, P; Delling, G; Epler, D; Fuchs, N; Graf, N; Heise, U; Jürgens, H; Körholz, D; Kotz, R; Salzer-Kuntschik, M; Weinel, P; Werner, M; Winkler, K, 1998)
"To estimate the duration of survival (S) of patients with metastatic osteosarcoma (MOS) at diagnosis treated with a multiagent, ifosfamide-containing chemotherapeutic and surgical regimen and to evaluate the toxicity of this regimen."5.08Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. ( Ayala, A; Ferguson, WS; Gieser, P; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1998)
"Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas."5.07An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993)
"Nine patients with osteosarcoma were treated by chemotherapy combined with caffeine and surgery."5.07Effect of chemotherapy combined with caffeine for osteosarcoma. ( Baba, H; Tomita, K; Tsuchiya, H; Ueda, Y; Yasutake, H; Yokogawa, A, 1992)
"In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)."5.06Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.91Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015)
"The efficacy of ifosfamide-based chemotherapy in the treatment of osteosarcoma has been investigated; however, results are inconsistent."4.91Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis. ( Cai, GP; Ding, GM; Fan, XL; Zhu, LL, 2015)
"We observed a correlation of higher planned methotrexate total dosage and DI with better treatment outcomes in osteosarcoma patients."4.90Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years. ( Li, B; Li, H; Li, Y; Sun, L; Ye, Z; Zhang, J, 2014)
"To assess testicular function after standard dose ifosfamide, we evaluated 6 young adult osteosarcoma survivors (median age at diagnosis, 16."4.90Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( Diller, L; Duffey-Lind, E; Ebb, D; Grier, H; Kenney, LB; Sklar, CA, 2014)
" The BSTTSG has currently been conducting a Phase III trial, JCOG 0905, to investigate the superiority of the addition of ifosfamide to the standard chemotherapy with methotrexate, cisplatin and doxorubicin for operable, high-grade osteosarcoma."4.88The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. ( Iwamoto, Y; Tanaka, K, 2012)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.88Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012)
"Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma."4.86Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.86Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010)
"At present, patients with nonmetastatic osteosarcoma of the extremity aged less than 40 years have an expected 5-year survival rate of 70% with a chemotherapy regimen based on methotrexate, cisplatin, doxorubicin and ifosfamide."4.84Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. ( Ferrari, S; Palmerini, E, 2007)
"Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma."4.82Ifosfamide in pediatric solid tumors. ( Bisogno, G; Carli, M; Passone, E; Perilongo, G, 2003)
"The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas."4.81Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001)
"Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease."4.79High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996)
"Using high-dose methotrexate, doxorubicin, and cisplatinum (or BCD) for adjuvant chemotherapy in osteosarcoma of the extremities, we achieved 8-year metastasis-free survival rates of 60-70%."4.78Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). ( Bielack, SS; Delling, G; Jürgens, H; Kotz, R; Salzer-Kuntschik, M; Winkler, K, 1993)
"We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985."4.78Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993)
" The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)."4.78Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992)
"Interval compression (IC), a regimen of alternating vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide every 2 weeks, improves survival for localized Ewing sarcoma (ES), with uncertain effect on metastatic disease."4.31Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression. ( Ghandour, K; Halalsheh, H; Ibrahimi, AKH; Ismael, T; Sarhan, N; Shehadeh, A; Sultan, I; Zandaki, D, 2023)
"We recruited 14 patients with osteosarcoma having acquirable lesions to establish PDX models and examine the sensitivity of nine drugs, including methotrexate (MTX), ifosfamide (IFO), epirubicin, and etoposide."4.31Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study. ( Chen, G; Ji, C; Li, J; Li, M; Long, Z; Lu, Y; Wang, Q; Wang, Z; Xiang, L; Yu, H, 2023)
"Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings."4.02Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021)
"The usefulness of adjuvant chemotherapy for high-grade osteosarcoma was established by two randomized, controlled trials conducted in the 1980s, which used six drugs, doxorubicin, cisplatin, high-dose methotrexate, bleomycin, cyclophosphamide and actinomycin D."4.02Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group. ( Hiraga, H; Ozaki, T, 2021)
"For Ewing sarcoma, interval-compressed vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide administered every 2 weeks rather than every 3 weeks has been shown to improve event-free survival in pediatric patients."3.96Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide. ( Bassale, S; Davis, LE; Lim, JY; Lu, E; Ryan, CW, 2020)
"Current treatment of high-grade osteosarcoma consists of preoperative chemotherapy, typically using some combination of doxorubicin, cisplatin, ifosfamide, and/or high-dose methotrexate followed by surgical resection."3.91Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation. ( Savani, M; Skubitz, KM, 2019)
"All treatment naive consecutive patients of osteosarcoma were prospectively treated on a novel institutional regimen (named OGS-12) comprising of eight sequential doublets of the following drugs: doxorubicin, cisplatin and ifosfamide in four courses each, given in the neoadjuvant and adjuvant settings."3.85Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. ( Bajpai, J; Banavali, SD; Chandrakanth, MV; Chandrasekharan, A; Ghosh, J; Gupta, S; Khan, A; Khurana, S; Rekhi, B; Simha, V; Talreja, V; Vora, T, 2017)
"Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide)."3.83Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Gebhardt, MC; Goorin, AM; Grier, HE; Healey, JH; Krailo, MD; Lipshultz, SE; Meyers, PA; Sato, JK; Schwartz, CL; Steinherz, LJ; Teot, LA; Wexler, LH, 2016)
"The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)."3.83Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016)
"Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma."3.81Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? ( Lin, F; Shen, Z; Tang, L; Yao, Y; Yu, W, 2015)
"In recent years, chemotherapy with caffeine has manifested potently high efficacy against osteosarcoma, although adverse effects have been observed."3.81Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles. ( Iwasaki, T; Kidani, T; Masumoto, J; Miura, H; Miyazaki, T; Nakamura, A; Nakata, H; Sakayama, K, 2015)
"The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma."3.81Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015)
"In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles (PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells."3.81Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015)
"Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide."3.80Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014)
"We sought to (1) evaluate the disease-specific survival at 2 and 5 years of patients with dedifferentiated chondrosarcoma; (2) assess the prognostic variables (both patient- and treatment-related), including the use of chemotherapy with ifosfamide, that relate to survivorship; and (3) assess specific toxicities associated with ifosfamide use."3.80Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? ( Deavers, M; Harun, N; Kawaguchi, S; Lewis, VO; Lin, PP; Sun, T, 2014)
"Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma."3.80Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014)
"We reviewed the records of 50 patients with osteosarcoma who underwent marginal resection following effective preoperative chemotherapy; 18 were treated with the MMIA (high-dose methotrexate (HD-MTX), adriamycin (ADR), ifosfamide (IFO)) and cisplatin (DDP), and 32 patients were treated with the DIA (DDP, ADR and IFO)."3.80Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes. ( Xu, M; Xu, S; Yu, X, 2014)
"This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma."3.80Ifosfamide-containing regimens for treating patients with osteosarcomas. ( Dong, YG; Jiang, XM; Li, YY; Ma, YB; Xu, G, 2014)
"A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)."3.80Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014)
"A 73-year-old man was diagnosed with osteosarcoma and treated with four cycles of preoperative chemotherapy with ifosfamide and doxorubicin followed by wide resection."3.79Metastasis of osteosarcoma to stomach made clinically evident by hematemesis: a case report. ( Arai, E; Futamura, N; Hirata, A; Ishiguro, N; Kozawa, E; Miyahara, R; Nishida, Y; Tsukushi, S; Tsurudome, I; Urakawa, H, 2013)
"To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University."3.79Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013)
"The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively."3.79Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. ( He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H, 2013)
"The objective of this study was to investigate the efficacy and toxic side effects of two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide on treating Chinese osteosarcoma patients."3.77Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. ( Dong, Y; Lin, F; Shen, Z; Sun, Y; Tang, L; Wang, Q; Yao, Y; Yu, W; Zheng, S, 2011)
"We retrospectively examined the incidence, severity, and risk factors of ifosfamide encephalopathy in 61 Japanese patients with bone and soft tissue sarcomas at our institution."3.76Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors. ( Kikuchi, S; Konno, S; Tajino, T; Takeda, A; Yamada, H, 2010)
"This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II."3.76Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. ( Chen, P; Lin, F; Sun, Y; Wang, Z; Yao, Y; Zhao, H, 2010)
"In an attempt to find leads to such markers, we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide, doxorubicin, and cisplatin."3.75Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. ( Bruheim, S; Fodstad, O; Ju, J; Xi, Y, 2009)
" Flow cytometric analyses by means of annexin-V and propidium iodide double staining and immunofluorescence staining of active caspase-3 revealed that cells subjected to a lethal dose of chloroacetaldehyde displayed features characteristic of necrosis and that caspase-3 was not activated in response to chloroacetaldehyde."3.74Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. ( Fujimoto, Y; Sakurai, K; Takahashi, K; Tanaka, H, 2007)
" We report a 9-year-old boy with osteosarcoma who experienced 2 episodes of pancreatitis 1 day and 48 days after infusion of ifosfamide (IFOS), respectively."3.74Acute pancreatitis associated with ifosfamide. ( Hung, GY; Hung, MC; Lin, PC; Tien, YC; Tiu, CM, 2007)
"Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor."3.73High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005)
"Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS)."3.73Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. ( Duan, X; Jia, SF; Kleinerman, ES; Koshkina, N, 2006)
"A 16-year-old girl with a distal femur osteosarcoma became pain-free with the first treatment of methotrexate 12."3.72Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. ( Cohen, IJ, 2003)
" During the initial therapy, an ifosfamide-induced encephalopathy occurred as status epilepticus."3.72Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide? ( Bellos, F; Egerer, G; Harter, C; Ho, AD; Kasper, B; Krasniqi, F; Meissner, J, 2004)
" Three drugs have recently been approved: Gleevec (imatinib mesylate) at a starting dose of 400 or 600 mg daily for the treatment of malignant unresectable and/or metastatic gastrointestinal stromal tumors; Mesnex (mesna) tablets as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis, and Zometa (zoledronic acid) for the treatment of patients with multiple myeloma and for patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy."3.71U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. ( Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA, 2002)
"To determine the activity of carboplatin/ifosfamide in patients with previously untreated osteosarcoma and to estimate patient outcomes after a multiagent chemotherapy protocol that eliminated cisplatin."3.71Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. ( Fletcher, BD; Harper, J; Jenkins, JJ; Mahmoud, HH; Marina, NM; Meyer, WH; Neel, M; Pappo, AS; Parham, DM; Poquette, CA; Pratt, CB; Rao, BN, 2001)
"Between January 1995 and December 1999, 11 patients with synchronous multifocal osteosarcoma (SMO) received neoadjuvant treatment with high-dose methotrexate, cisplatinum, Adriamycin, and ifosfamide."3.71Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. ( Bacci, G; Bernini, G; Biagini, R; Briccoli, A; Capanna, R; Donati, D; Fabbri, N; Ferrari, S; Longhi, A; Versari, M, 2001)
"Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor."3.70[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998)
"This prospective study was designed to test the activity of an ifosfamide-etoposide (VP-16) regimen on poor-risk, nonmetastatic, osteogenic sarcoma."3.70Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma. ( Ben Arush, MW; Drumea, K; Haim, N; Kuten, A; Meller, I; Moses, M; Stein, ME, 1998)
"A neoadjuvant chemotherapy protocol (1/93-1/95) for extremity osteosarcoma preoperatively using high-dose methotrexate (HDMTX) as single agent per cycle and three different combinations of other drugs (CDP/IFO,CDP/ADM,IFO/ADM) is reported."3.70Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study. ( Bacci, G; Bernini, G; Brach del Prever, A; Capanna, R; Cesari, M; Comandone, A; Ferrari, S; Longhi, A; Mercuri, M; Picci, P; Tienghi, A, 1998)
"Ifosfamide is a leading drug in soft tissue sarcoma therapy."3.70Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998)
"Ifosfamide and cisplatin are active agents that are currently used in the treatment of osteosarcoma."3.70Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. ( Arndt, C; Hawkins, D; Liedtke, R; Miser, J; Morgenstern, B; Wilson, D, 1999)
"We attempted to ascertain renal, hematologic, and neurologic tolerance to ifosfamide (IFX) in pediatric patients previously treated with large single and cumulative doses of cis-Diamminedichloroplatinum-II (CDP) for osteosarcoma (OS)."3.69Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations. ( Canpolat, C; Jaffe, N; Pearson, P; Robertson, R, 1996)
"A 20-year old man was treated for an osteosarcoma with a chemotherapy regimen that included ifosfamide, methotrexate, and doxorubicin."3.69Ifosfamide-induced Fanconi syndrome. ( Garcia, AA, 1995)
" A 16-year-old girl with metastatic osteosarcoma experienced recurrent bouts of symptomatic pancreatitis 24 hours after treatment with ifosfamide administered as a single agent."3.69Acute pancreatitis after ifosfamide therapy. ( Adamson, PC; Balis, FM; Blaney, SM; Izraeli, S, 1994)
"Three chemotherapy regimens comprised of doxorubicin, high dose methotrexate, cisplatin, and ifosfamide were retrospectively analyzed in 67 pediatric osteosarcoma patients."3.69Neoadjuvant chemotherapy for pediatric osteosarcoma patients. ( Araki, N; Myoui, A; Shinto, Y; Uchida, A; Ueda, T; Yoshikawa, H, 1997)
"High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma."3.69Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997)
"Eighteen patients with high grade malignant fibrous histiocytoma (MFH) of bone and 112 patients with high grade osteosarcoma (OS) of the extremity were treated with neoadjuvant chemotherapy comprised of methotrexate, cisplatinum, doxorubicin and ifosfamide."3.69Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. ( Bacci, G; Bertoni, F; Campanacci, M; Cesari, M; Ferrari, S; Forni, C; Gasbarrini, A; Mercuri, M; Sottili, S; Tienghi, A, 1997)
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)."3.69[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."3.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)."3.68Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993)
"To improve the accuracy of magnetic resonance imaging (MRI) in evaluating the response of osteosarcomas to preoperative chemotherapy, the authors developed a technique of mapping tumor necrosis and viability by quantitating slope values of gadolinium-DTPA (Gd-DTPA) uptake on dynamic fast low-angle shot (FLASH) images."3.68Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. ( Fairclough, DL; Fletcher, BD; Hanna, SL; Le, AH; Meyer, WH; Parham, DM, 1992)
"A 13-year-old boy with unresectable pulmonary metastatic osteosarcoma, which was refractory to high dose methotrexate, adriamycin, cisplatin and combination of bleomycin, cyclophosphamide and actinomycin D, was treated by aggressive chemotherapy including the combination of ifosfamide (1 g/m2 x day 1-4), Carboplatin (100 mg/m2 x day 1-4) and Vindesine (4 mg/m2 x day 1)."3.68[Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report]. ( Fujita, H; Ishimoto, K; Kiyokawa, N; Kyo, K; Mizuno, T; Takada, K; Yabuta, K, 1991)
"We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors."3.67A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986)
"Patients with cutaneous/subcutaneous Ewing sarcoma may have better prognosis than those with Ewing sarcoma at other anatomical sites."3.01Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma. ( Aiba, H; Arakawa, A; Imai, T; Iwata, S; Kawai, A; Kimura, H; Kobayashi, E; Kojima, Y; Ogawa, C; Shimoi, T; Sudo, K; Yazaki, S; Yonemori, K; Yoshida, A, 2023)
"Based on preclinical data for the antitumour effect of zoledronate in osteosarcoma, we assessed whether zoledronate combined with chemotherapy and surgery improved event-free survival in children and adults with osteosarcoma."2.82Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. ( Blay, JY; Bompas, E; Bonnet, N; Brisse, H; Brugières, L; Chevance, A; Corradini, N; Entz-Werlé, N; Gentet, JC; Gomez-Brouchet, A; Gouin, F; Guinebretière, JM; Italiano, A; Le Deley, MC; Lervat, C; Marec-Bérard, P; Mascard, E; Pacquement, H; Penel, N; Petit, P; Piperno-Neumann, S; Rédini, F; Tabone, MD, 2016)
"" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle."2.80Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015)
"Patients <30 years old with Ewing sarcoma were eligible."2.80Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015)
"The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue."2.76Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ( Billups, CA; Daw, NC; Jenkins, JJ; Luchtman-Jones, L; Neel, MD; Quintana, J; Rao, BN; Santana, VM; Villarroel, M; Wu, J, 2011)
"The European Intergroup Cooperative Ewing's Sarcoma Study investigated whether cyclophosphamide has a similar efficacy as ifosfamide in standard-risk (SR) patients and whether the addition of etoposide improves survival in high-risk (HR) patients."2.73Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. ( Cassoni, A; Craft, AW; Douglas, C; Dunst, J; Grimer, R; Hackshaw, A; Hunold, A; Jürgens, H; Köhler, G; Ladenstein, R; Lewis, I; McTiernan, A; Paulussen, M; Poremba, C; Schuck, A; Spooner, D; van den Berg, H; Whelan, J; Winkelmann, W; Zoubek, A, 2008)
"Median age at diagnosis of Ewing sarcoma was 12 years, and median length of follow-up, 8 years."2.73Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. ( Askin, FB; Bhatia, S; Burden, L; Chen, Z; Dickman, PS; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Perlman, EJ; Rausen, AR; Robison, LL; Vietti, TJ, 2007)
" The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome."2.71High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ( Crews, KR; Daw, NC; Link, MP; Liu, T; Meyer, WH; Panetta, JC; Rodriguez-Galindo, C; Tan, M, 2004)
"Grade 3 thrombocytopenia was observed in five cases (36%)."2.71Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005)
" was applied in combination with high-dose methotrexate (HDMTX) and adriamycin (ADM) within a three-drug regimen."2.70A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. ( Bacchini, P; Bacci, G; Bertoni, F; De Giorgi, U; Ferrari, S; Fiorentini, G; Forni, C; Longhi, A; Mercuri, M; Picci, P; Rimondini, S; Tienghi, A, 2001)
"Six hundred ninety Ewing tumor patients were treated between 1992 and 1999 with local therapy and vincristine."2.70Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. ( Ahrens, S; Aulitzky, WE; Dunst, J; Fölsch, UR; Göbel, U; Harms, D; Hense, HW; Henze, G; Jürgens, H; Kremens, B; Lehnert, M; Niemeyer, C; Paulussen, M; Reiter, A; Taeger, D; Voûte, PA; Wagner, A; Zoubek, A, 2001)
"Two hundred one patients had no metastases."2.69Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. ( Cotterill, S; Craft, A; Grimer, R; Imeson, J; Lewis, I; Malcolm, A; Souhami, R; Spooner, D, 1998)
"The Cooperative Ewing Sarcoma Study (CESS 86), conducted by the German Society of Pediatric Oncology and Hematology (GPOH), was planned on the basis of the results of the preceding CESS 81 study."2.69Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. ( Ahrens, S; Braun-Munzinger, G; Dunst, J; Göbel, U; Harms, D; Heinecke, A; Hoffmann, C; Jabar, S; Jürgens, H; Paulussen, M; Rübe, C; Treuner, J; Winkelmann, W; Winkler, K, 1999)
"The first Scandinavian protocol for Ewing's sarcoma, SSG IV, resulted in a local control rate of 74% and 5-year metastasis-free survival (MFS) of 43%."2.69Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. ( Akerman, M; Alvegård, TA; Björk, O; Blomqvist, CP; Elomaa, I; Saeter, G; Stenwig, E; Wiebe, T, 2000)
"Malignant fibrous histiocytoma (MFH) is a rare bone tumor usually treated like osteosarcoma."2.68Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. ( Bacci, G; Ferrari, S; Mercuri, M; Picci, P, 1997)
"Extraosseous Ewing sarcoma is a rare, poorly differentiated round-cell tumour that is part of the Ewing sarcoma family of tumours."2.61Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature. ( Khalifeh, I; Maroun, CA; Moukarbel, RV; Tfayli, A, 2019)
"Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s."2.52Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials. ( Lai, Z; Lin, Y; Mo, Y; Su, W; Wu, F; Wu, J; Yang, Z, 2015)
"Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration."2.52An update on chemotherapy for osteosarcoma. ( Ferrari, S; Serra, M, 2015)
"Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in eradicating primary tumor and pulmonary metastases in the mid-twentieth century."2.50Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. ( Jaffe, N, 2014)
"While most invasive primary breast cancers are epithelial derived adenocarcinomas, rare neoplasms such as the phyllodes tumor may arise from mesenchymal tissue."2.49Unusual aggressive breast cancer: metastatic malignant phyllodes tumor. ( Singer, A; Tresley, J; Velazquez-Vega, J; Yepes, M, 2013)
"Here, we present an approach to the treatment of Ewing sarcoma in a patient with PFIC1."1.91Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease. ( Bailey, KM; Daley, J; Friehling, E; Halligan, K; Howrie, D; Salgado, CM; Superdock, A, 2023)
"Osteosarcoma is one of the most common childhood bone malignancies."1.91Outcomes and survival rates of childhood osteosarcoma in Iran, A report from MAHAK Pediatric Cancer Treatment and Research Center, from 2007 to 2020. ( Mehrvar, A; Mehrvar, N; Sadeghi, Y; Tashvighi, M, 2023)
"However, because sarcoma is very rare, there is little evidence regarding the management of elderly patients with sarcoma."1.72Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. ( Ozaki, T; Tanaka, K, 2022)
"Most aspects of osteosarcoma have been addressed in detail, but there is no comprehensive analysis of deceased patients and causes of death."1.72Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS). ( Bielack, SS; Blattmann, C; Borkhardt, A; Csóka, M; Hassenpflug, W; Hecker-Nolting, S; Kabíčková, E; Kager, L; Kessler, T; Kevric, M; Kratz, C; Kühne, T; Lehrnbecher, T; Mayer-Steinacker, R; Mettmann, V; Metzler, M; Reichardt, P; Rossig, C; Sorg, B; von Luettichau, I; Windhager, R, 2022)
"Osteosarcoma is the most common primary bone malignancy in both children and adults."1.62A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma. ( Bui, NQ; Charville, GW; Ganjoo, KN; Hu, BD; Pribnow, A; Saadeh, NL; Spunt, SL; Testa, S, 2021)
"Adult Ewing sarcoma (ES) is a rare disease, the optimal treatment model is unknown."1.51Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. ( He, A; Hu, H; Huang, Y; Shen, Z; Sun, Y; Yao, Y; Zhang, J; Zhou, Y, 2019)
"The management of osteosarcoma is challenging especially in lower-income and middle-income countries, and there is an unmet need to evolve efficient and sustainable chemotherapy regimens."1.51Osteosarcoma journey over two decades in India: Small steps, big changes. ( Bajpai, J; Banavali, S; Chandrasekharan, A; Ghosh, J; Gupta, S; Hingmare, S; Mandal, T; Rangarajan, B; Rekhi, B; Shah, K; Shetty, N; Simha, V; Vora, T, 2019)
"Ifosfamide (IFA) is a potent alkylating antitumoral agent, but its use is limited by neurological side effects."1.48Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases. ( Bellien, J; Duflot, T; Filhon, B; Joannidès, R; Lamoureux, F; Marie-Cardine, A; Massy-Guillemant, N; Pereira, T; Verstuyft, C, 2018)
"Considering the physical condition of patient, the patient underwent surgical resection of the right lung lesion after receiving endostar combined with chemotherapy and maintained endostar alone for 47 cycles."1.46Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( Dong, Y; Jiang, S; Wang, G, 2017)
"Patients with bones or brain metastases were treated with palliative radiotherapy only or combined with Doxorubicin."1.43Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast. ( Blecharz, P; Jakubowicz, J; Kulpa, J; Mituś, JW; Reinfuss, M; Walasek, T, 2016)
"The incidence of Ewing sarcoma is lower in non-Caucasian populations, compared with Caucasian populations, for unknown reasons."1.43Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma. ( Aoki, Y; Araki, N; Hamada, K; Imura, Y; Joyama, S; Kakunaga, S; Naka, N; Obata, H; Takenaka, S; Ueda, T; Yoshikawa, H, 2016)
"Data on patients with localized Ewing sarcoma family of tumors (ESFT) who have received a uniform chemotherapy protocol are minimal."1.42Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol. ( Agarwala, S; Bakhshi, S; Biswas, B; Deo, SV; Khan, SA; Mohanti, BK; Rastogi, S; Sharma, MC; Shukla, NK; Vishnubhatla, S, 2015)
"A 9-year-old girl with Ewing sarcoma had one ovary excised and cryopreserved prior to chemo- and radiotherapy."1.39Case report: stimulation of puberty in a girl with chemo- and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue. ( Andersen, CY; Birkebæk, NH; Clausen, N; Ernst, E; Kjærsgaard, M, 2013)
"Mice implanted with Ewing's sarcoma tumours received the following treatments: saline, ifosfamide, ifosfamide + NAC concurrently, pre-treatment with NAC + ifosfamide, or NAC alone."1.38The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model. ( Figueredo, R; Hanly, L; Koren, G; Koropatnick, J; Rieder, MJ, 2012)
"Alveolar soft part sarcomas are rarely seen and highly malignant tumors, and the prognosis of stage IV ASPS is poor."1.38[Treatment and prognosis of stage IV alveolar soft part sarcoma]. ( Yang, Y; Zhao, J, 2012)
"Information is scarce on systemic treatment of pelvic osteosarcoma because most chemotherapy protocols for osteosarcoma include patients with extremity tumors and aged up to 30-40 years."1.38Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years. ( Alberghini, M; Fabbri, N; Ferrari, C; Ferrari, S; Palmerini, E; Picci, P; Staals, E, 2012)
"Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments."1.37Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011)
"We evaluated whether Korean Ewing sarcoma family of tumors patients have poorer outcomes than Euro-American patients."1.37Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience. ( Cho, J; Cho, WH; Jeon, DG; Kim, DH; Kim, MS; Koh, JS; Kong, CB; Lee, JA; Lee, SY; Lim, JS; Song, WS; Yoo, JY, 2011)
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity."1.37High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011)
"Ifosfamide is a widely used chemotherapeutic agent for the treatment of a broad spectrum of solid tumors."1.36Ifosfamide-induced encephalopathy and movement disorder. ( Ames, B; Chaffee, S; Kim, J; Lewis, LD; Morse, R, 2010)
"The emergence of a primitive neuroectodermal tumor (PNET) within a germ-cell tumor (GCT) is rare."1.36Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor. ( Andreoiu, M; Beck, SDW; Brames, MJ; Cheng, L; Ehrlich, Y; Einhorn, LH; Foster, RS; Ulbright, TM, 2010)
"Neuroblastoma is the most common extracranial solid malignancy in children but rarely described in adults, being 10% of all cases diagnosed after the first decade of life."1.36Neuroblastoma in an adult: case report. ( Ferreti Bonan, PR; Martelli-Júnior, H; Miranda Soares, PB; Pereira DE Souza, W; Quirino Filho, S, 2010)
"We present a case of pleomorphic malignant fibrous histiocytoma arising from the left forearm in a 45-year-old man who had undergone resection and radiotherapy for a tumor 3 years previously."1.35Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy. ( Hoshi, M; Ieguchi, M; Takami, M, 2008)
"The outcome of Ewing's sarcoma depends on the anatomical site of the tumor."1.35Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone. ( Arpaci, F; Ataergin, S; Beyzadeoglu, M; Komurcu, S; Oysul, K; Ozet, A; Ozturk, M; Solchaga, L; Surenkok, S; Turan, M, 2009)
"After a search for Ewing tumors in the database of a single institution over a period of 20 years, 16 out of 192 cases were found to have extra-osseous primary tumors."1.35Extra-osseous Ewing sarcoma. ( Heinen, RC; Merks, JH; van den Berg, H; van der Pal, HJ, 2009)
"The effect of immunotherapy with interleukin-18 (IL-18) in combination with preoperative chemotherapy on the postoperative progression of pulmonary metastasis was examined using a spontaneous pulmonary metastasis model of mouse osteosarcoma."1.35Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. ( Futani, H; Hata, M; Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamanegi, K, 2009)
"Advances in the treatment of Ewing sarcoma family of tumors (ESFT) are the result of improvements in systemic and local therapies."1.35Prognostic factors for local and distant control in Ewing sarcoma family of tumors. ( Billups, CA; Krasin, MJ; Liu, T; Navid, F; Rao, BN; Rodríguez-Galindo, C, 2008)
"Forty patients with localized Ewing sarcoma (ES) were treated with primary site RT at one institution."1.34Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. ( Mai, WY; Nguyen, TX; Paulino, AC; Teh, BS; Wen, BC, 2007)
"From 1979 to 2002, 27 patients with Ewing's sarcoma (20) or PNET (7) were treated."1.34Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands. ( Boven, E; Meijer, OW; Smorenburg, CH; van Groeningen, CJ; Visser, M, 2007)
" Adverse reactions (AR) were evaluated; quality assurance of data collection reviewed."1.33Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. ( Craft, A; Juergens, C; Juergens, H; Lewis, I; Michon, J; Oberlin, O; Paulussen, M; Weston, C; Whelan, J; Zoubek, A, 2006)
"The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma."1.32Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. ( Bielack, SS; Branscheid, D; Flege, S; Gadner, H; Jundt, G; Jürgens, H; Kabisch, H; Kager, L; Kastner, U; Kempf-Bielack, B; Kotz, R; Pötschger, U; Reichardt, P; Salzer-Kuntschik, M; Winkelmann, W; Zoubek, A, 2003)
"Thirty-seven patients had distant metastases at presentation."1.32Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003)
"An ileoilealic intussusception was found, caused by a small bowel tumour, which almost completely obstructed the intestinal lumen."1.32Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report. ( Boehm, R; Joppich, I; Landes, J; Schmid, I; Till, H, 2003)
"Spinal cord compression has also been rarely reported in all age groups."1.32Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent. ( Akansel, G; Arisoy, AE; Calişkan, M; Corapcioglu, F; Dillioğlugil, O; Sarper, N, 2004)
"Osteosarcoma is the most common primary malignant tumor of bone (annual incidence: 2 - 3/Mio)."1.32[Goal and results of the COSS study]. ( Bielack, S; Flege, S, 2004)
"Despite the fact that Ewing sarcoma family of tumors (ET) is chemosensitive, long-term survival is extremely rare for patients with primary refractory or recurrent disease."1.32VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. ( Allam, A; Bazarbashi, S; El Foudeh, M; El Hassan, I; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, M, 2004)
"Older age and axial location of Ewing's sarcoma have been reported as unfavorable prognostic factors."1.32Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment. ( Argon, A; Basaran, M; Bavbek, SE; Camlica, H; Darendeliler, E; Dizdar, Y; Onat, H; Ozger, H; Sakar, B; Yaman, F, 2004)
"Although the overall results of treatment of Ewing's tumors have improved, patients with high-risk factors, including metastatic disease at diagnosis, bulky primary tumors, axial sites, and age >15 years, continue to have poor prognoses."1.31High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors. ( Iwamoto, Y; Matsuda, S; Matsunobu, T; Sakamoto, A; Tanaka, K, 2002)
"Ewing sarcoma is the second most common bone tumor in childhood."1.31Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. ( Delattre, O; Poupon, MF; Sancéau, J; Sastre-Garau, X; Wietzerbin, J, 2002)
"Data on 359 patients with nonmetastatic Ewing's sarcoma of bone treated at a single institution between January 1979 and April 1995 were retrospectively considered."1.31Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. ( Bacchini, P; Bacci, G; Bertoni, F; Donati, D; Ferrari, S; Forni, C; Longhi, A; Manfrini, M; Picci, P; Rimondini, S, 2000)
"Patients had Ewing's sarcoma/primitive neuroectodermal tumour (PNET), rhabdomyosarcoma, non-rhabdo soft tissue sarcomas or other advanced soft tissue tumours."1.31Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. ( Daller, RT; Fenton, JG; Miser, JS; Womer, RB, 2000)
"Our 35-year-old patient had atypical carcinoid tumor metastatic to cervical, supraclavicular, mediastinal, and mesenteric lymph nodes and to the liver and bone."1.31High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor. ( Anthony, LB; Drouant, G; Espanan, GD; Maloney, TJ; McCarthy, KE; Meyers, MO; Woltering, EA, 2000)
"A young woman presented with a pineoblastoma treated initially with whole neuraxis radiotherapy."1.31Long-term survival following extra-neural metastasis from a pineoblastoma. ( Fraser, G; Nicoll, J; Rampling, R; Smith, C; Stephen, M, 2000)
"Cooperative Ewing's Sarcoma Study (CESS) 86 aimed at improving event-free survival (EFS) in patients with high-risk localized Ewing tumor of bone."1.31Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. ( Ahrens, S; Amann, G; Dockhorn-Dworniczak, B; Dunst, J; Exner, GU; Gadner, H; Göbel, U; Harms, D; Janka-Schaub, G; Jürgens, H; Kornhuber, B; Kotz, R; Müller-Weihrich, S; Paulussen, M; Treuner, J; Voûte, PA; Welte, K; Winkelmann, W; Zoubek, A, 2001)
"We describe a 16-year-old girl with a Ewing sarcoma who was given post-operative treatment with HDI (15 mg/m(2) infused over 5 days)."1.31Painful peripheral neuropathy after treatment with high-dose ifosfamide. ( Frisk, P; Stålberg, E; Strömberg, B, 2001)
"Osteosarcoma is a primary malignancy of bone."1.31Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. ( Berend, KR; Dibernardo, L; Harrelson, JM; Moore, JO; Pietrobon, R; Scully, SP, 2001)
"Since 1985, 54 with localized Ewing's sarcoma of bone were treated at the Onco-Orthopedics Clinic of the Sofia University Hospital (Sofia, Bulgaria)."1.31[Treatment of Ewing's sarcoma with 2 different protocols]. ( Mihova, A; Mumdjiev, I; Sokolov, T; Stoianova, A, 2001)
"Records of 34 patients with ES/PNET who received the IVAD chemotherapy regimens were reviewed."1.30The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. ( Fisher, C; Harmer, CL; Judson, IR; Thomas, JM; Verrill, MW; Wiltshaw, E, 1997)
"The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas."1.30Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998)
"Chondrosarcomas are alleged to be resistant to chemotherapy."1.30Chemotherapy and P-glycoprotein expression in chondrosarcoma. ( Albino, AP; Devaney, K; Glantz, L; Healey, JH; Mak, S; Schwartz, GK; Terek, RM, 1998)
"The patient died due to brain metastases 20 months after the start of intra-arterial chemotherapy."1.30[A case of metastatic liver tumors from prostatic cancer responding to intra-arterial infusion chemotherapy with CDDP and ifosfamide using implantable port]. ( Hasegawa, N; Kazama, A; Kondo, N; Tomita, M, 1999)
"The OHS osteosarcoma tumors caused sclerotic lesions with high and uniform isotope uptake, and the MHMX unclassified sarcoma showed a mixed pattern with both sclerotic and lytic areas, whereas the LOX melanoma caused lytic bone lesions with low uptake of the radionuclide."1.29Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. ( Bruland, O; Fodstad, O; Kjønniksen, I; Winderen, M, 1994)
" Moreover, a dose-response relationship was detectable: 1/6 patients without lung irradiation vs."1.29Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. ( Dunst, J; Jürgens, H; Paulussen, M, 1993)
" For this first step a daily dosage of 300 mg/m2 of body surface resulted in only moderate leukopenia, whereas a daily dosage of 450 mg/m2 caused severe leukopenia."1.29Development of a canine chemotherapeutic model with ifosfamide. ( Chao, EY; Donehower, RC; Frassica, FJ; Ikeda, K; Inoue, N; Tomita, K, 1996)
"Twelve patients with localized Ewing's sarcoma were treated between 1980-1990 at the Istanbul School of Medicine, Department of Pediatric Oncology-Hematology, Oncology Research and Treatment Center and Our Children Leukemia Foundation."1.28Ewing's sarcoma: experience with 12 cases. ( Gedikoğlu, G; Zülfikar, B, 1992)
"Two cases of Ewing's sarcoma originating from the adult rib were reported."1.28[Two cases of Ewing's sarcoma originating from the adult rib]. ( Akiba, Y; Fujita, Y; Ikushima, Y; Ishida, S; Ohosaki, Y; Onodera, S; Sakai, E; Saotome, K; Shimizu, T; Tagaki, S, 1991)

Research

Studies (413)

TimeframeStudies, this research(%)All Research%
pre-199011 (2.66)18.7374
1990's106 (25.67)18.2507
2000's137 (33.17)29.6817
2010's128 (30.99)24.3611
2020's31 (7.51)2.80

Authors

AuthorsStudies
Testa, S1
Hu, BD1
Saadeh, NL1
Pribnow, A1
Spunt, SL3
Charville, GW1
Bui, NQ1
Ganjoo, KN1
Tanaka, K4
Ozaki, T4
Zandaki, D1
Ismael, T1
Halalsheh, H2
Ibrahimi, AKH1
Sarhan, N1
Ghandour, K1
Shehadeh, A2
Sultan, I2
Stacchiotti, S2
Van der Graaf, WTA1
Sanfilippo, RG1
Marreaud, SI1
Van Houdt, WJ1
Judson, IR2
Gronchi, A3
Gelderblom, H7
Litiere, S3
Kasper, B4
Luminais, SN1
Chen, XT1
Roman, D1
Ma, B1
Christ, AB1
Hu, JS1
Lucari, B1
Tallis, E1
Sutton, VR1
Porea, T1
Bielack, SS8
Blattmann, C1
Borkhardt, A1
Csóka, M1
Hassenpflug, W1
Kabíčková, E1
Kager, L3
Kessler, T1
Kratz, C1
Kühne, T3
Kevric, M2
Lehrnbecher, T1
Mayer-Steinacker, R2
Mettmann, V1
Metzler, M1
Reichardt, P2
Rossig, C1
Sorg, B1
von Luettichau, I1
Windhager, R1
Hecker-Nolting, S1
Corvest, V1
Marec-Bérard, P10
Lervat, C3
Pacquement, H6
Toulmonde, M1
Gentet, JC8
Laurence, V6
Cleirec, M1
Mansuy, L1
Bompas, E4
Castex, MP2
Taque, S2
Filhon, B2
Tabone, MD5
Verité, C1
Entz-Werle, N4
Saumet, L2
Guimard, G1
Pondrom, M1
Chevreau, C2
Flandrin, J1
Duranteau, L1
Rousset-Jablonski, C1
Brugières, L6
Jimenez, M1
Le Deley, MC8
Gaspar, N7
Fresneau, B1
Brennan, B5
Kirton, L2
Martín-Broto, J4
Sastre, A3
Owens, C3
Fenwick, N3
Strauss, S3
Moroz, V3
Whelan, J7
Wheatley, K5
Daley, J1
Halligan, K1
Howrie, D1
Salgado, CM1
Superdock, A1
Friehling, E1
Bailey, KM1
Long, Z1
Lu, Y1
Li, M1
Ji, C1
Chen, G1
Li, J2
Xiang, L1
Yu, H1
Wang, Q2
Wang, Z4
Aiba, H1
Kojima, Y1
Shimoi, T1
Sudo, K1
Yazaki, S1
Imai, T1
Yoshida, A1
Iwata, S2
Kobayashi, E1
Kawai, A2
Arakawa, A1
Ogawa, C1
Kimura, H1
Yonemori, K1
Mehrvar, A1
Mehrvar, N1
Sadeghi, Y1
Tashvighi, M1
Foroughi, A1
Arefpour, AM1
Nikoofar, A1
Sanei, M1
Mahdavi, SH1
Javadinia, SA1
Cash, T1
Krailo, MD8
Buxton, AB1
Pawel, BR2
Healey, JH7
Binitie, O1
Marcus, KJ2
Grier, HE13
Grohar, PJ1
Reed, DR1
Weiss, AR2
Gorlick, R4
Janeway, KA3
DuBois, SG3
Womer, RB7
Salah, S1
Abuhijla, F1
Ismail, T1
Yaser, S1
Abdelal, S1
Almousa, A1
Jaber, O1
Abu-Hijlih, R1
Maroun, CA1
Khalifeh, I1
Tfayli, A1
Moukarbel, RV1
Zhang, J2
Huang, Y2
Sun, Y5
He, A2
Zhou, Y1
Hu, H1
Yao, Y8
Shen, Z6
Anderton, J1
Kaiser, S1
Fernández-Pinto, M1
Evans, A1
Lu, E1
Ryan, CW1
Bassale, S1
Lim, JY1
Davis, LE1
Zhang, B1
Zhang, Y2
Li, R1
Lu, X1
D'Ambrosio, L1
Touati, N1
Blay, JY6
Grignani, G2
Flippot, R1
Czarnecka, AM1
Piperno-Neumann, S4
Sanfilippo, R1
Katz, D1
Duffaud, F2
Vincenzi, B1
Stark, DP1
Mazzeo, F1
Tuchscherer, A1
Sherriff, J1
Estival, A1
Sents, W1
Ray-Coquard, I2
Tolomeo, F1
Le Cesne, A4
Rutkowski, P1
Totadri, S1
Bansal, D1
Rao, KLN1
Jain, R1
Saxena, AK1
Kapoor, R1
Samujh, R1
Trehan, A1
Han, J1
Yu, Y1
Wu, S1
Zhang, W1
Zhao, M1
Hu, Y1
Wang, W3
Liu, X1
Yu, W4
Cheng, J1
Yu, L1
Bao, Q1
Zhang, G1
Yu, X2
Song, R1
Verma, P1
Jain, S1
Kapoor, G1
Tripathi, R1
Sharma, P1
Doval, DC1
Sarbay, H1
Demir, ÜF1
Yılmaz, G1
Atay, AA1
Malbora, B1
Howe, AS1
Pearce, J1
Lian, F1
Ribbons, L1
Chumbalkar, V1
Nazeer, T1
Kogan, BA1
Bajpai, J3
Panda, GS1
Chandrasekharan, A3
Bhargava, P1
Srinivas, S1
Laskar, S1
Dandekar, S1
Mokal, S1
Rekhi, B3
Khanna, N1
Menon, N1
Patil, V1
Noronha, V1
Joshi, A1
Prabhash, K1
Banavali, SD2
Gupta, S3
Koscielniak, E1
Sparber-Sauer, M1
Scheer, M1
Vokuhl, C1
Kazanowska, B1
Ladenstein, R3
Niggli, F1
Ljungman, G1
Paulussen, M13
Seitz, G1
Fuchs, J1
Hallmen, E1
Klingebiel, T1
Paul, A1
Duncan, A1
Bacchetta, J1
Dubourg, L2
Tanné, C1
Hiraga, H1
Campbell-Hewson, Q1
Huang, J1
Okpara, CE1
Bautista, F1
Kim, SH2
Shin, KH3
Moon, SH1
Kong, Y1
Suh, JS2
Yang, WI2
Young, RJ1
Lia, M1
Hogendoorn, PCW1
Fisher, C2
Mechtersheimer, G1
Daugaard, S1
Sciot, R1
Collin, F1
Messiou, C1
Grünwald, V1
van der Graaf, W1
Wardelmann, E1
Judson, I3
Teepen, JC1
van Leeuwen, FE1
Tissing, WJ1
van Dulmen-den Broeder, E1
van den Heuvel-Eibrink, MM1
van der Pal, HJ2
Loonen, JJ1
Bresters, D1
Versluys, B1
Neggers, SJCMM1
Jaspers, MWM1
Hauptmann, M1
van der Heiden-van der Loo, M1
Visser, O1
Kremer, LCM1
Ronckers, CM1
Deng, ZP1
Liu, BY1
Jin, T1
Li, B2
Ding, Y1
Niu, XH1
Talreja, V1
Simha, V2
Chandrakanth, MV1
Khurana, S1
Khan, A1
Vora, T2
Ghosh, J2
Ahmed, SK1
Randall, RL2
Harmsen, WS1
Krailo, M6
Geller, DS1
Sorger, JI1
Granowetter, L3
Gorlick, RG1
Laack, NNI1
Meazza, C1
Cefalo, G3
Massimino, M2
Daolio, P2
Pastorino, U1
Scanagatta, P1
Morosi, C1
Podda, M2
Ferrari, A2
Terenziani, M1
Spreafico, F1
Casanova, M1
Parafioriti, A2
Collini, P1
Gandola, L3
Bastoni, S1
Biassoni, V1
Schiavello, E1
Chiaravalli, S1
Puma, N1
Bergamaschi, L1
Luksch, R4
Occean, BV2
Bouvier, C1
Brisse, HJ1
Cheurfa, N1
Corradini, N3
Delaye, J2
Italiano, A3
Mascard, E2
Redini, F3
Schmitt, C4
Verite-Goulard, C1
Duflot, T1
Marie-Cardine, A1
Verstuyft, C1
Pereira, T1
Massy-Guillemant, N1
Joannidès, R1
Bellien, J1
Lamoureux, F2
Jiang, S1
Wang, G1
Dong, Y2
Savani, M1
Skubitz, KM1
Jamshidi, K1
Ramezan Shirazi, M1
Bagherifard, A1
Mirzaei, A1
Zhang, SP1
Li, X1
Li, H2
Sun, XH1
Yan, XF1
Paasch, C1
De Santo, G1
Boettge, KR1
Strik, MW1
Wakamatsu, T1
Kakunaga, S2
Takenaka, S2
Outani, H1
Hamada, K3
Imura, Y2
Hori, Y1
Naka, N3
Kudawara, I2
Yoshikawa, H5
Ueda, T7
Mandal, T1
Shah, K1
Hingmare, S1
Rangarajan, B1
Shetty, N1
Banavali, S1
Cupissol, D1
Perrin, C1
Penel, N3
Rios, M1
Anract, P2
de Pinieux, G2
Collard, O1
Bertucci, F1
Aoki, Y2
Araki, N3
Nakanishi, H1
Matsumine, A2
Ieguchi, M2
Mori, S1
Myoui, A3
Kuratsu, S1
Hashimoto, N2
Urakawa, H1
Tsukushi, S1
Tsurudome, I1
Hirata, A1
Arai, E1
Kozawa, E1
Futamura, N1
Miyahara, R1
Ishiguro, N1
Nishida, Y1
Palmerini, E9
Maki, RG2
Staals, EL1
Alberghini, M4
Antonescu, CR1
Ferrari, C3
Ruggieri, P10
Mavrogenis, A1
Bertoni, F14
Cesari, M10
Paioli, A2
Marchesi, E2
Picci, P23
Ferrari, S42
Bi, W1
Han, G2
Jia, J1
Xu, M3
Choeyprasert, W2
Natesirinilkul, R1
Charoenkwan, P1
Sittipreechacharn, S1
Singer, A1
Tresley, J1
Velazquez-Vega, J1
Yepes, M1
Al-Hader, AA1
Jain, A1
Al-Nasrallah, N1
Einhorn, LH2
Kobys, VL1
Konovalenko, VF1
Repinа, NV1
Golovko, TS1
Gulak, LO1
Tarasova, TO1
Zaharycheva, EV1
Matyushok, OF1
Lionel, AP1
Chinnaswamy, G1
John, RR1
Mathai, S1
Yoo, C1
Lee, J2
Rha, SY2
Park, KH1
Kim, TM1
Kim, YJ1
Lee, HJ1
Lee, KH1
Ahn, JH2
Fagioli, F6
Tamburini, A4
Abate, ME3
Balladelli, A5
Pratelli, L2
Nishimura, H1
Enokida, H1
Nagano, S1
Yokouchi, M1
Hayami, H1
Komiya, S1
Nakagawa, M1
Kawaguchi, S1
Sun, T1
Lin, PP2
Deavers, M1
Harun, N1
Lewis, VO2
Boye, K1
Del Prever, AB3
Eriksson, M3
Saeter, G4
Tienghi, A8
Lindholm, P2
Skjeldal, S1
Hall, KS4
Robert, G1
Chappé, C1
Bruneau, B1
Gandemer, V1
Cao, J1
Huang, XE1
Liu, J2
Wu, XY1
Lu, YY1
Sun, L1
Li, Y1
Ye, Z1
Kenney, LB1
Duffey-Lind, E1
Ebb, D1
Sklar, CA1
Grier, H2
Diller, L1
Kushnir, I1
Kolander, Y1
Bickels, J2
Gortzak, Y1
Flusser, G1
Issakov, J2
Merimsky, O3
Jaffe, N4
Lewis, I6
Ranft, A2
Le Teuff, G2
Michon, J2
van den Berg, H4
Hjorth, L3
Juergens, H3
Craft, A4
Oberlin, O4
Dirksen, U3
Raciborska, A1
Bilska, K1
Drabko, K1
Chaber, R1
Sobol, G1
Pogorzała, M1
Wyrobek, E1
Połczyńska, K1
Rogowska, E1
Rodriguez-Galindo, C6
Wożniak, W1
Seok, SO1
Cho, YJ1
Noh, JK1
Hung, GY2
Yen, HJ1
Yen, CC1
Chen, WM1
Chen, PC1
Wu, HT1
Chiou, HJ1
Chang, WH1
Hsu, HE1
Xu, S1
Xiao, X1
Whelan, JS4
Marina, N6
Smeland, S6
Jovic, G1
Hook, JM1
Anninga, J1
Butterfass-Bahloul, T1
Böhling, T2
Calaminus, G1
Capra, M1
Deffenbaugh, C1
Dhooge, C1
Flanagan, AM1
Goorin, A2
Gosheger, G2
Grimer, RJ1
Helmke, K1
Hogendoorn, PC2
Jundt, G2
Kuehne, T1
Lau, CC1
Letson, GD1
Meyer, J3
Meyers, PA11
Morris, C1
Mottl, H1
Nadel, H3
Nagarajan, R1
Schomberg, P1
Schwarz, R1
Teot, LA2
Sydes, MR1
Bernstein, M4
Tang, L2
Lin, F4
Vredenburg, G1
den Braver-Sewradj, S1
van Vugt-Lussenburg, BM1
Vermeulen, NP1
Commandeur, JN1
Vos, JC1
Li, YY1
Jiang, XM1
Dong, YG1
Xu, G1
Ma, YB1
Pakakasama, S1
Sirachainan, N1
Songdej, D1
Chuansumrit, A1
Anurathapan, U1
Hongeng, S1
Nartthanarung, A1
Biswas, B1
Rastogi, S2
Khan, SA2
Shukla, NK1
Deo, SV1
Agarwala, S1
Mohanti, BK1
Sharma, MC2
Vishnubhatla, S2
Bakhshi, S2
Su, W1
Lai, Z1
Wu, F1
Lin, Y1
Mo, Y1
Yang, Z1
Wu, J2
Hattinger, CM2
Michelacci, F1
Sella, F1
Magagnoli, G1
Benini, S2
Gambarotti, M1
Serra, M5
Magnan, H1
Goodbody, CM1
Riedel, E1
Pratilas, CA1
Wexler, LH4
Chou, AJ1
Nakata, H1
Miyazaki, T1
Iwasaki, T1
Nakamura, A1
Kidani, T1
Sakayama, K1
Masumoto, J1
Miura, H1
Huang, YJ1
He, AN1
Sun, YJ1
Min, DL1
Brunetto, AL2
Castillo, LA1
Petrilli, AS2
Macedo, CD1
Boldrini, E1
Costa, C1
Almeida, MT2
Kirst, D1
Pereira, WV1
Watanabe, FM1
Pizza, M1
Benites, E1
Morais, V1
Gadelha, A1
Nakasato, A1
Abujamra, AL1
Gregianin, LJ1
Vulsteke, C1
Lurquin, E1
Debiec-Rychter, M1
Gheysens, O1
Nuyts, S1
Schoenaers, J1
Politis, C1
Mebis, J1
Hauben, E1
Clement, PM1
Saste, A1
Cabrera Fernandez, DF1
Gulati, R1
Gamalski, S1
Karski, EE1
McIlvaine, E1
Segal, MR1
Felgenhauer, J2
Ladenstein, RL1
Kruseova, J1
Brichard, B1
Shkalim-Zemer, V1
Ash, S2
Toledano, H1
Kollender, Y2
Yaniv, I2
Cohen, IJ3
Nataraj, V1
Batra, A1
Schwartz, CL4
Devidas, M3
Steinherz, LJ1
Goorin, AM5
Gebhardt, MC6
Sato, JK1
Bernstein, ML4
Lipshultz, SE1
Mulder, RL3
Paulides, M4
Langer, T4
Kremer, LC3
van Dalen, EC3
Mituś, JW1
Blecharz, P1
Walasek, T1
Reinfuss, M1
Jakubowicz, J1
Kulpa, J1
Chen, B1
Yang, JZ1
Wang, LF1
Zhang, YJ1
Lin, XJ1
Mascarenhas, L1
Felgenhauer, JL1
Bond, MC1
Villaluna, D1
Femino, JD1
Laack, NN1
Ranganathan, S1
Fan, XL1
Cai, GP1
Zhu, LL1
Ding, GM1
Ben-Ami, T1
Waldman, E1
Marc, W1
Weintraub, M1
Revel-Vilk, S1
Fried, I1
Yonemoto, T2
Takahashi, M1
Maru, M1
Tomioka, A1
Saito, M1
Araki, Y1
Tazaki, M1
Tsuchiya, M1
Kamoda, H1
Ishii, T4
Yılmaz, S1
Özçakar, ZB1
Taktak, A1
Kiremitçi, S1
Ensari, A1
Dinçaslan, H1
Yalçınkaya, F1
Obata, H2
Joyama, S1
Nodomi, S1
Umeda, K1
Okamoto, T1
Saida, S1
Hiramatsu, H1
Watanabe, K1
Adachi, S1
Heike, T1
Petit, P1
Brisse, H1
Gomez-Brouchet, A1
Guinebretière, JM2
Gouin, F2
Chevance, A1
Bonnet, N1
Miolo, G1
Viel, A1
Canzonieri, V2
Baresic, T1
Buonadonna, A1
Santeufemia, DA1
Lara, DP1
Corona, G1
Biason, P1
Iacoboni, E1
Gagno, S1
Fanelli, M1
Tavanti, E1
Vella, S1
Roli, A1
Roncato, R1
Giodini, L1
Scotlandi, K2
Toffoli, G1
Zhang, T1
Zhang, S1
Yang, F1
Wang, L1
Zhu, S1
Qiu, B1
Li, S1
Deng, Z1
Helman, LJ1
Reaman, GH1
Craft, AW2
Hackshaw, A1
Douglas, C1
Dunst, J9
Schuck, A3
Winkelmann, W6
Köhler, G1
Poremba, C1
Zoubek, A7
Hunold, A1
Cassoni, A1
Spooner, D3
Grimer, R3
McTiernan, A3
Jürgens, H18
Ottaviani, S1
Forest, A1
Descamps, V1
Meyer, O1
Dieudé, P1
Hoshi, M1
Takami, M1
Ataergin, S1
Ozet, A1
Solchaga, L1
Turan, M1
Beyzadeoglu, M1
Oysul, K1
Arpaci, F1
Komurcu, S1
Surenkok, S1
Ozturk, M1
Tomita, Y1
Inoue, A1
Fujimoto, T2
Hatazawa, J1
Osanai, T1
Tsuchiya, T1
Sugawara, M1
Pintoffl, J1
Meisinger, I1
Mayer, F1
Horger, M1
von Weyhern, C1
Kanz, L2
Hartmann, JT1
Womer, R2
Wang, C1
Leavey, P1
Gebhardt, M2
Healey, J2
Shamberger, RC1
Miser, J3
Arndt, CA3
Sailer, S2
Marcus, K2
Perlman, E1
Dickman, P1
Ding, L1
Wang, HX1
Xue, M1
Zhu, L1
Yan, HM1
Duan, LN1
Wang, ZD1
Staals, E2
Longhi, A17
Bacci, G34
Berretta, M1
Zanet, E1
Taibi, R1
Martellotta, F1
Pavone, P1
Bearz, A1
Gobitti, C1
Ciancia, EM1
Tirelli, U1
Heinen, RC1
Merks, JH1
Briccoli, A8
Rocca, M2
Salone, M1
Di Fiore, M1
Zoccali, C1
Prencipe, U1
Ferraresi, V1
Salducca, N1
Lashkari, A1
Chow, WA1
Valdes, F1
Leong, L1
Phan, V1
Twardowski, P1
Kapoor, N1
Molina, A1
Al-Kadhimi, Z1
Frankel, P1
Somlo, G1
Peeters, J1
Meitert, J1
Beck, JD1
Bölling, T1
Ernst, I1
Willich, N3
Yamada, N1
Hata, M1
Ohyama, H1
Yamanegi, K1
Kogoe, N1
Nakasho, K1
Futani, H2
Okamura, H1
Terada, N2
Bruheim, S1
Xi, Y1
Ju, J1
Fodstad, O2
Ames, B1
Lewis, LD1
Chaffee, S1
Kim, J1
Morse, R1
Jung, S1
Cai, JY1
Tang, JY1
Pan, C1
Xue, HL1
Zhou, M1
Dong, L1
Ye, QD1
Jiang, H1
Shen, SH1
Chen, J1
Tajino, T1
Kikuchi, S1
Yamada, H1
Takeda, A1
Konno, S1
Gatcombe, HG1
Olson, TA1
Esiashvili, N1
Ehrlich, Y1
Beck, SDW1
Ulbright, TM1
Cheng, L1
Brames, MJ1
Andreoiu, M1
Foster, RS1
Xing, PY1
Shi, YK1
Feng, FY1
Qin, Y1
Liu, P1
Zhao, H2
Chen, P1
Machak, GN1
Polotskiĭ, BE1
Meluzova, OM1
Chernov, IS1
Aliev, MD1
Buchbinder, D1
Steinberg, G1
Linetsky, M1
Casillas, J1
Lindet, C1
Vanhuyse, M1
Thebaud, E1
Robin, YM1
Indelicato, DJ1
Keole, SR1
Lagmay, JP1
Morris, CG1
Gibbs, CP1
Scarborough, MT2
Islam, S1
Marcus, RB1
Odri, GA1
Dumoucel, S1
Picarda, G1
Battaglia, S1
Rousseau, J1
Tirode, F1
Laud, K1
Delattre, O2
Heymann, D1
Gougelet, A1
Pissaloux, D1
Besse, A1
Perez, J1
Duc, A1
Dutour, A1
Alberti, L1
Sundby Hall, K1
Wiebe, T3
Alvegard, TA4
Brach Del Prever, A5
Mercuri, M20
Capanna, R5
Mapelli, S1
Prete, A2
Carli, M2
Barbieri, E9
Miranda Soares, PB1
Quirino Filho, S1
Pereira DE Souza, W1
Ferreti Bonan, PR1
Martelli-Júnior, H1
Wang, Y1
Bi, WZ1
Wang, DJ1
Lu, SB1
Zhang, L1
Zhao, B1
Lee, JA1
Kim, DH1
Cho, J1
Lim, JS1
Koh, JS1
Yoo, JY1
Kim, MS1
Kong, CB1
Song, WS1
Cho, WH1
Lee, SY1
Jeon, DG1
Cui, Q1
Jiang, W1
Guo, J1
Liu, C1
Li, D1
Wang, X1
Zeng, Y1
Bruland, OS1
Brosjö, O2
Bjerkehagen, B1
Osterlundh, G1
Jakobson, A1
Monge, OR1
Björk, O2
Alvegaard, TA1
Daw, NC3
Neel, MD3
Rao, BN7
Billups, CA5
Jenkins, JJ4
Quintana, J1
Luchtman-Jones, L1
Villarroel, M1
Santana, VM2
Hong, S1
Shin, SJ1
Jung, M1
Jeong, J1
Lee, YJ1
Roh, JK1
Braquet, P1
Chapelle, A1
Jorgensen, C1
Pers, YM1
Lee, SH1
Chang, MH1
Baek, KK1
Han, B1
Lim, T1
Park, JO1
Mirza, T1
Ameerally, P1
Zheng, S2
Fernandez-Pineda, I1
Bahrami, A1
Green, JF1
McGregor, LM1
Davidoff, AM2
Sandoval, JA1
Zils, K1
Ebner, F1
Ott, M1
Müller, J1
Baumhoer, D1
Greulich, M1
Rehnitz, D1
Rempen, A1
Schaetzle, S1
Wilhelm, M1
Bielack, S5
Fukunaga, S1
Tsukamoto, Y1
Ono, J1
Okamoto, N2
Otsuka, Y1
Tanizawa, T1
Tomatsuri, M1
Yoshiya, S1
Qi, W1
Yang, Y3
Comandone, A5
Bertulli, R1
Bisogno, G3
Linari, A1
Iwamoto, Y2
Punanov, IuA1
Gafton, GI1
Gudz', IuV1
Nabokov, VV1
Ivanova, TV1
Safonova, SA1
Levchenko, EV1
Kupatadze, DD1
Novik, VI1
Lazareva, IuR1
Krzhivitskiĭ, PI1
Petrov, VG1
Yamada, SM1
Ishii, Y1
Yamada, S1
Kuribayashi, S1
Kumita, S1
Matsuno, A1
Min, D1
Tan, L1
Dede, DS1
Aksoy, S1
Cengiz, M1
Gullu, I1
Altundag, K1
Kuperman, AA1
Kornreich, L1
Feinmesser, M1
Batschinski, K1
Dervisis, NG1
Kitchell, BE1
Hanly, L1
Figueredo, R1
Rieder, MJ1
Koropatnick, J1
Koren, G1
Ernst, E1
Kjærsgaard, M1
Birkebæk, NH1
Clausen, N1
Andersen, CY1
West, DC1
Dickman, PS4
Dormans, JP1
Zhao, J1
Fabbri, N8
Hervonen, P1
Lehtinen, T1
Tammela, TL1
Kellokumpu-Lehtinen, P1
Matsunobu, T1
Sakamoto, A1
Matsuda, S1
Patel, SJ1
Lynch, JW1
Johnson, T1
Carroll, RR1
Schumacher, C1
Spanier, S1
Scarborough, M1
Sancéau, J1
Poupon, MF1
Sastre-Garau, X1
Wietzerbin, J1
Cohen, MH1
Dagher, R1
Griebel, DJ1
Ibrahim, A1
Martin, A1
Scher, NS1
Sokol, GH1
Williams, GA1
Pazdur, R1
Janinis, J1
Driver, D1
Mitchell, C1
Cassoni, AM1
Pringle, J1
Kilby, A1
Reverter-Branchat, G1
Manara, MC1
Incaprera, M1
Tarbell, NJ3
Link, MP6
Fryer, CJ3
Pritchard, DJ3
Perlman, EJ3
Donaldson, SS3
Moore, S2
Rausen, AR3
Vietti, TJ3
Miser, JS6
Macchiagodena, M1
Vitali, G1
Dalpiaz, O1
al Rabi, N1
Galfano, A1
Martignoni, G1
Ficarra, V1
Artibani, W1
Pötschger, U1
Kastner, U1
Flege, S2
Kempf-Bielack, B1
Branscheid, D1
Kotz, R7
Salzer-Kuntschik, M6
Kabisch, H1
Gadner, H3
Ogose, A1
Yazawa, Y1
Hotta, T1
Kawashima, H1
Hatano, H1
Morita, T1
Donati, D5
Bacchini, P4
Giacomini, S1
Forni, C16
Manfrini, M4
Galletti, S2
Kolb, EA1
Kushner, BH2
Laverdiere, C1
LaQuaglia, MP2
Huvos, AG1
Qin, J1
Vu, HT1
Wexler, L1
Wolden, S1
Boehm, R1
Till, H1
Landes, J1
Schmid, I1
Joppich, I1
Passone, E1
Perilongo, G1
De Paolis, M1
Setola, E1
Harter, C1
Meissner, J1
Bellos, F1
Krasniqi, F1
Ho, AD1
Egerer, G1
Inbar, M1
Meller, I2
Raj, AB1
Bertolone, SJ1
Zalupski, MM1
Rankin, C1
Ryan, JR1
Lucas, DR1
Muler, J1
Lanier, KS1
Budd, GT1
Biermann, JS1
Meyers, FJ1
Antman, K2
Crews, KR1
Liu, T2
Tan, M1
Meyer, WH8
Panetta, JC1
Takahashi, S2
Okada, K1
Nagasawa, H1
Shimada, Y1
Sakamoto, H1
Itoi, E1
Patel, SR4
Papadopolous, N2
Raymond, AK1
Donato, M1
Seong, CM1
Yasko, AW1
Champlin, R1
Benjamin, RS4
Guo, W1
Yang, RL1
Tang, XD1
Tang, S1
Li, DS1
Goto, T2
Kosaku, H1
Kobayashi, H1
Hozumi, T2
Kondo, T2
Chuman, H1
Krasin, MJ2
Merchant, TE2
Kun, LE2
Corapcioglu, F1
Dillioğlugil, O1
Sarper, N1
Akansel, G1
Calişkan, M1
Arisoy, AE1
Berrak, SG1
Pearson, M1
Berberoğlu, S1
Ilhan, IE1
El Weshi, A1
Memon, M1
Raja, M1
Bazarbashi, S1
Rahal, M1
El Foudeh, M1
Pai, C1
Allam, A1
El Hassan, I1
Ezzat, A1
Argon, A1
Basaran, M2
Yaman, F1
Dizdar, Y1
Sakar, B2
Camlica, H1
Bavbek, SE1
Ozger, H2
Darendeliler, E1
Onat, H2
Yalcin, B2
Pamir, A2
Buyukcelik, A1
Utkan, G1
Akbulut, H2
Demirkazik, A2
Icli, F2
Berta, M1
Watanabe, A1
Taniguchi, M1
Suzuki, M2
Kume, H1
Matsumoto, S2
Nishimatsu, H1
Tomita, K3
Kitamura, T1
Kleinerman, ES4
Betcher, D2
Conrad, E1
Ferguson, W2
Harris, MB3
Huvos, A1
Link, M2
Montebello, J1
Nieder, M2
Sato, J1
Siegal, G1
Weiner, M1
Wells, R1
Wold, L1
Dillman, RO1
Barth, NM1
VanderMolen, LA1
Allen, K1
Beutel, LD1
Chico, S1
Pierga, JY1
Barthier, S1
Babinet, A1
Alapetite, C1
Palangié, T1
Pouillart, P1
Dinçbaş, FO1
Koca, S1
Mandel, NM1
Hiz, M1
Dervişoğlu, S1
Seçmezacar, H1
Oksüz, DC1
Ceylaner, B1
Uzel, B1
Virolainen, P1
Inoue, N2
Nagao, M1
Frassica, FJ2
Chao, EY2
Pieretti, F1
Verri, E1
Tolentinis, L1
Versari, M4
Zolezzi, C2
Lamanna, G2
Ng, A1
Hobson, R1
Williams, D1
Morland, B1
Zak, D1
Styler, MJ1
Rosenbluth, JZ1
Brodsky, I1
La, TH1
Alektiar, KM1
Boland, PJ1
Wolden, SL1
Meyer, T1
Michelagnoli, MP2
Eselgrim, M1
Grunert, H1
Bürger, H1
Bernini, G3
Müller, C1
Gordon, N1
Hawkins, DS1
Doherty, DK1
Inwards, CY1
Munsell, MF1
Stewart, J1
Koshkina, NV1
McCarville, MB2
Cain, AM4
Duan, X1
Jia, SF1
Koshkina, N1
de Camargo, B1
Filho, VO1
Bruniera, P1
Jesus-Garcia, R1
Camargo, OP1
Pena, W1
Péricles, P1
Davi, A1
Prospero, JD1
Alves, MT1
Oliveira, CR1
Macedo, CR1
Mendes, WL1
Borsato, ML1
dos Santos, TM1
Ortega, J1
Consentino, E1
Milano, GM1
Cozza, R1
Ilari, I1
De Sio, L1
Boldrini, R1
Jenkner, A1
De Ioris, M1
Inserra, A1
Dominici, C1
Donfrancesco, A1
Navid, F2
Furman, WL1
Hale, GA1
Pappo, AS4
Juergens, C1
Weston, C1
Sanchez-Mejia, RO1
Ojemann, SG1
Simko, J1
Chaudhary, UB1
Levy, J1
Lawton, MT1
Ruiz Tovar, J1
Reguero Callejas, ME1
Arano Bermejo, JI1
Capote Armas, LF1
González-Palacios Martínez, F1
Cabañas Navarro, L1
Paulino, AC1
Nguyen, TX1
Mai, WY1
Teh, BS1
Wen, BC1
Escobosa Sánchez, OM1
Herrero Hernández, A1
Ortega Acosta, MJ1
Camacho Alonso, J1
Milano Manso, G1
Acha García, T1
Anderson, P2
Kołłataj, B1
Zajaczkowska, M1
Katski, K1
Sikora, P1
Pijanowska, M1
Majewski, M1
Kołłataj, W1
Yock, TI1
Chen, Z2
Laurie, F1
Bhatia, S1
Burden, L1
Askin, FB1
Robison, LL1
Kalifa, C5
Nogi, H1
Kobayashi, T1
Kawase, K1
Tabei, I1
Toriumi, Y1
Kawakami, M1
Morikawa, T1
Uchida, K1
Naru, T1
Nawaz, FH1
Rizvi, J1
Abe, S1
Tsuchiya, H2
Yabe, H1
Al-Faris, N1
Al Harbi, T1
Goia, C1
Pappo, A1
Doyle, J1
Gassas, A1
Pichon, F1
Vanel, D2
Dupoüy, N1
Takenaka, M1
Okamoto, Y1
Ikeda, K2
Hashimoto, R1
Kurokawa, N1
Takagi, T1
Uejima, E1
Takahashi, K2
Sakurai, K1
Tanaka, H1
Fujimoto, Y1
Burke, MJ1
Walterhouse, DO1
Jacobsohn, DA1
Duerst, RE1
Kletzel, M1
Smorenburg, CH1
van Groeningen, CJ1
Meijer, OW1
Visser, M1
Boven, E1
Hung, MC1
Lin, PC1
Tiu, CM1
Tien, YC1
Lorigan, P1
Verweij, J3
Papai, Z1
Rodenhuis, S1
Leahy, MG1
Radford, JA1
Van Glabbeke, MM1
Kirkpatrick, A1
Okuma, T1
Nakada, I1
Han, JQ1
Han, CY1
Bi, YH1
Iagaru, A1
Masamed, R1
Chawla, SP1
Menendez, LR1
Fedenko, A1
Conti, PS1
Bavbek, ES1
Saglam, S1
Eralp, L1
Atalar, AC1
Bilgic, B1
Mahajan, A1
Woo, SY1
Kornguth, DG1
Hughes, D1
Huh, W1
Chang, EL1
Herzog, CE2
Pelloski, CE1
Ferguson, WS2
Harris, M1
Kleinerman, E1
Siegal, GP2
Weiner, MA1
Wells, RJ1
Takeuchi, S1
Akahoshi, Y1
Kasai, C1
Nishimoto, Y1
Utracka-Hutka, B1
Czownicki, Z1
König, HJ1
Hartwich, G1
Canpolat, C1
Pearson, P1
Robertson, R1
Küpfer, A1
Aeschlimann, C1
Wermuth, B1
Cerny, T2
Carpentier, AF1
Chantelard, JV1
Henin, D1
Poisson, M1
Sauer, R1
Pape, H1
Rübe, C5
Sugihara, S1
Hamada, M1
Nakagawa, Y1
Inoue, H1
Garcia, AA1
Winkler, K7
Delling, G5
Delepine, N3
Delepine, G3
Desbois, JC2
Razafindrakoto, H1
Vassal, G1
Contesso, G1
Edeline, V1
Valteau, D1
Lemerle, J2
Kattan, J1
Culine, S1
Theodore, C1
Droz, JP1
Kawaguchi, N1
Manabe, J1
Kuroda, H1
Shimoji, T1
Rodary, C1
Raquin, M1
Valteau-Couanet, D1
Izraeli, S1
Adamson, PC1
Blaney, SM1
Balis, FM2
Elomaa, I2
Pratt, CB5
Parham, DM6
Fleming, ID1
Rock, MG1
Shives, TC1
Gilchrist, GS1
Smithson, WA1
Edmonson, JH1
Schaid, DJ1
Schvartzman, E1
Scopinaro, M1
Muriel, FS1
Rosen, G1
Kjønniksen, I1
Winderen, M1
Bruland, O1
Rosito, P6
Ferraro, A2
Casadei, R2
Kálmánchey, R1
Koós, R1
Majtényi, K1
Borsi, J1
Devalck, C1
Tempels, D1
Ferster, A1
De Laet, MH1
Bujan, W1
Heiman, P1
Sariban, E2
Fujita, K1
Matsushima, H1
Nakano, M1
Kaneko, T1
Crowley, J1
Balcerzak, SP1
Rivkin, SE1
Weiss, GR1
Elias, A2
Natale, RB1
Cooper, RM1
Barlogie, B1
Trump, DL1
Umeda, T2
Kitoh, M2
Tatezaki, S2
Satoh, T2
Gururangan, S1
Bowman, LC1
Wilimas, JA1
Rao, B2
Douglass, EC1
Legha, SS1
Nicaise, C1
Toma, S1
Palumbo, R1
Canavese, G1
Albanese, E1
Cantoni, E1
Barisone, A1
Reggiardo, G1
Rosso, R1
Santi, L1
Lobo-Sanahuja, F1
García, I1
Santamaría, S1
Barrantes, JC1
Lowry, PA1
Carstens, C1
Soslow, RA1
Davis, RE1
Warnke, RA1
Cleary, ML1
Kamel, OW1
Demetri, GD1
Stein, ME2
Ruff, P1
Weaving, A1
Fried, J1
Bezwoda, WR1
Iantorno, D2
Campanacci, M5
DeLaney, TF1
Tsokos, M1
Avila, N1
Steinberg, SM1
Weaver-McClure, L1
Jacobson, J1
Jarosinski, P1
Hijazi, YM1
Horowitz, ME1
Roguin, A1
Ben Arush, MW2
Higasi, A1
Kuten, A2
Tella, G1
Donehower, RC1
Uchida, A1
Shinto, Y1
Fetscher, S1
Brugger, W1
Engelhardt, R1
Hasse, J1
Frommhold, H1
Wenger, M1
Lange, W1
Mertelsmann, R1
Leo, E1
Schlegel, PG1
Lindemann, A1
Brunat-Mentigny, M7
Demaille, MC2
Pein, F1
Avet-Loiseau, H1
Berger, C1
De Lumley, L1
Pillon, P1
Bernard, JL1
Vadhan-Raj, S1
Plager, C1
Burgess, MA2
Hays, C1
Bellmunt, J1
Eres, N1
Ribas, A1
Casado, S1
Albanell, J1
Baselga, J1
Sottili, S1
Gasbarrini, A2
Murad, AM1
Guimaraes, RC1
Amorim, WC1
Morici, AC1
Ferreira-Filho, AF1
Schwartsmann, G1
Tesoro-Tess, JD1
Gianni, MC1
Fossati-Bellani, F1
Lombardi, F1
Chap, LI1
Mirra, J1
Ippolito, V1
Rentschler, R1
Rosen, P1
Nielsen, OS1
Therasse, P1
van Oosterom, AT1
Chou, CW1
Liu, JM1
Wu, MF1
Li, AF1
Tie, CM1
Chi, KH1
Verrill, MW1
Wiltshaw, E1
Thomas, JM1
Harmer, CL1
Hirota, T1
Takeuchi, M1
Iwata, A1
Kitagawa, S1
Sato, T1
Konno, K1
Sawada, K1
Kobayashi, S1
Hamaguchi, N1
Agata, H1
Katano, N1
Moses, M1
Drumea, K1
Haim, N1
Koch Nogueira, PC1
Hadj-Aïssa, A1
Schell, M1
Cochat, P1
Ahrens, S6
Harms, D4
Leyvraz, S1
Bacchi, M1
Lissoni, A1
Sessa, C1
Bressoud, A1
Hermann, R1
Fuchs, N1
Epler, D1
Bieling, P2
Körholz, D1
Graf, N1
Heise, U2
Weinel, P2
Werner, M1
Cotterill, S1
Malcolm, A1
Souhami, R1
Imeson, J1
Gieser, P1
Ayala, A1
Shochat, SJ1
Holbrook, T1
Terek, RM1
Schwartz, GK1
Devaney, K1
Glantz, L1
Mak, S1
Albino, AP1
Leone, L1
Oliva, C1
Frustaci, S1
Monteleone, M1
Colussi, AM1
Dal Canton, O1
Bergnolo, P1
Boglione, A1
Bumma, C1
Lindner, NJ1
Spanier, SS1
Enneking, WF1
Hofmann, J1
Hillmann, A1
Mancini, A1
Rimondini, S3
Di Liddo, M1
Arndt, C1
Morgenstern, B1
Hawkins, D2
Wilson, D1
Liedtke, R1
Mancini, AF1
Baldini, N1
Hoffmann, C1
Jabar, S1
Braun-Munzinger, G1
Heinecke, A1
Göbel, U4
Treuner, J3
Lewis, IJ1
Gattamaneni, HR1
Bailey, CC1
Lashford, LS1
Fasano, MC1
Czyzewski, EA1
Goldman, S1
Mundt, AJ1
Nachman, J1
Rubin, C1
Hallahan, DE1
Le Chevalier, T2
Missenard, G1
Lepechoux, C1
Cojean-Zelek, I1
Mesurolle, B1
Kondo, N1
Tomita, M1
Hasegawa, N1
Kazama, A1
Marina, NM3
Poquette, CA3
Greenwald, C1
Thomson, B1
Radich, J1
Souid, AK1
Fahey, RC1
Dubowy, RL1
Newton, GL1
Philip, T1
Iliescu, C1
Krakowski, I1
Soler-Michel, P1
Thiesse, P1
Chauvin, F1
Shankar, AG1
Pinkerton, CR1
Atra, A1
Ashley, S1
Cannon, S1
Cotterill, SJ2
Loro, L1
Mazzei, T1
Beghelli, C1
Biolchini, A1
Simoni, P1
Tremosini, M1
Strazzari, S1
Puggioli, C1
Daller, RT1
Fenton, JG1
Blomqvist, CP1
Akerman, M1
Stenwig, E1
Dinçol, D1
Samur, M1
Sencan, O1
Onur, H1
Senler, FC1
Skinner, R1
Stevens, MC1
Meyers, MO1
Anthony, LB1
McCarthy, KE1
Drouant, G1
Maloney, TJ1
Espanan, GD1
Woltering, EA1
Fraser, G1
Rampling, R1
Smith, C1
Nicoll, J1
Stephen, M1
Mahmoud, HH1
Harper, J1
Neel, M1
Fletcher, BD3
Böhm, P1
Kunz, W1
Horny, HP1
Einsele, H1
Brandao, L1
Zavatta, M1
Fiorentini, G1
De Giorgi, U1
Exner, GU1
Amann, G1
Dockhorn-Dworniczak, B1
Müller-Weihrich, S1
Welte, K1
Kornhuber, B1
Janka-Schaub, G1
Voûte, PA2
Campanacci, L1
Biagini, R1
Frisk, P1
Stålberg, E1
Strömberg, B1
Stewart, SL1
Cormier, JN1
Ballo, MT1
Feig, BW1
Hunt, KK1
Raney, RB1
Zagars, GK1
Pisters, PW1
Berend, KR1
Pietrobon, R1
Moore, JO1
Dibernardo, L1
Harrelson, JM1
Scully, SP1
Lehnert, M1
Taeger, D1
Hense, HW1
Wagner, A1
Reiter, A1
Henze, G1
Niemeyer, C1
Kremens, B1
Fölsch, UR1
Aulitzky, WE1
Ito, T1
Mochida, A1
Saito, K1
Nishi, K1
Sasaki, S1
Hisada, T1
Morinari, H1
Nakahara, K1
Tahara, M1
Masuda, S1
Yakumaru, K1
Sokolov, T1
Stoianova, A1
Mumdjiev, I1
Mihova, A1
Könemann, S1
Rübe, CE1
Lari, S1
Estrada-Aguilar, J1
Greenberg, H1
Walling, A1
Schroer, K1
Black, T1
Morse, S1
Hvizdala, E1
Kun, L1
Roberson, P1
Parham, D1
Fletcher, B1
Zülfikar, B1
Gedikoğlu, G1
Blackledge, G1
Steward, WP1
Mouridsen, H1
Bramwell, V1
Schütte, J1
van Oosterom, A1
Dombernowsky, P1
Buesa, J1
Van Glabekke, M1
Antman, KH2
Yasutake, H1
Yokogawa, A1
Baba, H1
Ueda, Y1
Habrand, JL1
Zucker, JM2
Terrier-Lacombe, MJ1
Dubousset, J1
Ponvert, D1
Carrié, C1
Scher, CS1
Amar, D1
McDowall, RH1
Barst, SM1
Hanna, SL1
Fairclough, DL1
Le, AH1
Thomas, F1
Subirana, R1
Baldeyrou, P1
Ruffie, P1
Arriagada, R1
Chazard, M1
Tursz, T1
Lewis, CR1
Fossà, SD1
Mead, G1
ten Bokkel Huinink, W1
Harding, MJ1
Mill, L1
Paul, J1
Jones, WG1
Rodenburg, CJ1
Cantwell, B1
Dose, C1
Ritter, J4
Petrilli, S1
Penna, V1
Lopes, A1
Figueiredo, MT1
Gentil, FC1
Pignatti, G1
De Cristofaro, R1
Dallari, D1
Avella, M1
Marangolo, M1
Ferruzzi, A1
Fujita, H1
Kiyokawa, N1
Takada, K1
Kyo, K1
Ishimoto, K1
Yabuta, K1
Mizuno, T1
Ishida, S1
Akiba, Y1
Ohosaki, Y1
Onodera, S1
Fujita, Y1
Tagaki, S1
Shimizu, T1
Sakai, E1
Ikushima, Y1
Saotome, K1
Iwasaku-Fujimoto, M1
Fujiwara, F1
Todo, S1
Morioka, Y1
Imashuku, S1
Lemmi, MA1
Slade, W1
Greenshaw, C1
Kusnierz-Glaz, C1
Erttmann, R1
Biron, P1
Kohler, R1
Blondet, R1
Bérard, J1
Chauvot, P1
Bouffet, E1
Carret, JP1
Jonas, P1
Patricot, LM2
Purfürst, C1
Nourissat, C1
Tachon, G1
Manoukian, A1
Exner, U1
Kühl, J1
Ryan, L1
Sulkes, A1
Collins, J1
Aisner, J1
Deméocq, F1
Benz-Lemoine, E1
Boilletot, A1
Behar, C1
Poutard, P1
Olive, D1
Tsukagoshi, S1
Taillard, F1
Desbois, JG1
Cornille, H1
Jasmin, C1
Mathé, G1
Legmann, F1
Magrath, I1
Sandlund, J1
Raynor, A1
Rosenberg, S1
Arasi, V1

Clinical Trials (29)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosa[NCT04154189]Phase 281 participants (Actual)Interventional2020-03-23Completed
A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153]Phase 241 participants (Actual)Interventional2010-04-30Completed
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007]Phase 2/Phase 337 participants (Actual)Interventional2016-03-31Completed
European Ewing Tumour Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G.99)[NCT00020566]Phase 31,200 participants (Anticipated)Interventional2001-02-28Recruiting
Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR[NCT04461223]55 participants (Anticipated)Observational [Patient Registry]2019-12-01Recruiting
A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy[NCT00134030]Phase 31,334 participants (Actual)Interventional2005-11-14Completed
Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma[NCT00987636]Phase 3907 participants (Actual)Interventional2009-10-01Completed
OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant[NCT00470223]Phase 3318 participants (Actual)Interventional2007-03-31Active, not recruiting
Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma[NCT04890067]120 participants (Anticipated)Observational2021-07-30Recruiting
Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment[NCT00824083]950 participants (Actual)Observational2009-07-31Completed
Chemotherapy-induced Necrosis in Ewing Sarcoma: Which is the Best Scoring Tool[NCT03968471]474 participants (Actual)Observational2019-05-13Completed
EUROPEAN INTERGROUP COOPERATIVE EWING'S SARCOMA STUDY [EICESS 92][NCT00002516]Phase 30 participants Interventional1992-07-31Active, not recruiting
Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893]100 participants (Anticipated)Observational2021-06-01Recruiting
Trial of Chemotherapy Intensification Through Compression in Ewing's Sarcoma and Related Tumors[NCT00006734]Phase 3587 participants (Actual)Interventional2001-05-31Completed
Prospective Evaluation of the Prognostic Relevance of PCR Positivity in Blood and Bone Marrow in Non-Metastatic Ewings Sarcoma[NCT00339898]414 participants (Actual)Observational2004-03-12Completed
Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study[NCT03737435]80 participants (Anticipated)Observational2018-12-12Recruiting
A Pilot Study of Tumor Vaccination and R-hIL-7 Following Standard Multimodality Therapy in Patients With High Risk Pediatric Solid Tumors[NCT00923351]Phase 1/Phase 244 participants (Actual)Interventional2007-06-02Completed
A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors[NCT01259479]Phase 19 participants (Actual)Interventional2010-12-03Completed
SFOP-OS94: Multicentric Randomised Phase III Trial Comparing Efficacy of Preoperative High-Dose Methotrexate Plus Doxorubicin to Efficacy of High-Dose Methotrexate Plus Etoposide and Ifosfamide, in Children and Adolescents Osteosarcoma[NCT00180908]Phase 3226 participants Interventional1994-06-30Completed
Randomized Phase III Trial of Two Investigational Schedules of Ifosfamide vs. Standard Dose Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT00003212]Phase 3780 participants (Anticipated)Interventional1998-01-31Completed
MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Osteosarcoma After Resection Of Pulmonary Metastases[NCT05726383]Phase 232 participants (Anticipated)Interventional2023-12-15Not yet recruiting
Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471]Phase 244 participants (Actual)Interventional2009-07-31Completed
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma[NCT00802880]Phase 280 participants (Actual)Interventional2009-03-31Completed
Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300]Phase 2/Phase 30 participants (Actual)Interventional2017-11-06Withdrawn (stopped due to No participants enrolled)
INTENSIVE THERAPY WITH GROWTH FACTOR SUPPORT FOR PATIENTS WITH EWING'S TUMOR METASTATIC AT DIAGNOSIS: A PEDIATRIC ONCOLOGY GROUP PHASE II STUDY[NCT00002643]Phase 2130 participants (Actual)Interventional1995-04-30Completed
Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097]82 participants (Actual)Observational2014-04-15Completed
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595]Phase 20 participants (Actual)Interventional2009-02-28Withdrawn (stopped due to No patients accrued since study opened)
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma[NCT01755195]Phase 255 participants (Actual)Interventional2013-01-15Active, not recruiting
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas[NCT00043979]Phase 260 participants (Actual)Interventional2002-09-19Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Scale: Generic Core Scale Score at Month 4

Health-Related Quality of Life (HRQoL): PedsQL 4.0 Generic Core Scale is a multidimensional scale. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (5 items - children greater than or equal to [>=] 5 years, adults; 3 items - toddlers [aged 2-4 years]). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Generic Core Scale total score: sum of all the items divided by the number of items answered across all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Baseline and Month 4

Interventionscore on a scale (Mean)
Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide2.61
Treatment Arm B: Ifosfamide + Etoposide2.65

Change From Baseline in PedsQL Scale: Cancer Module Scale Score at Month 4

HRQoL: PedsQL 3.0 Cancer Module Scale measured pediatric cancer-specific HRQoL. It included assessment of 8 dimensions: pain and hurt (2 items), nausea (5 items), procedural anxiety (3 items), treatment anxiety (3 items), worry (3 items), cognitive problems (3 items - toddlers [aged 2-4], 4 items - young children [aged 5-7]; 5 items for children aged >=8 years, adults), perceived physical appearance (3 items), communication (3 items). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Cancer Module total score: sum of all items divided by the number of items answered on all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Baseline and Month 4

Interventionscore on a scale (Mean)
Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide2.66
Treatment Arm B: Ifosfamide + Etoposide2.08

Objective Response Rate at Month 4 (ORR-4m) by IIR Assessment

ORR-4m was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) as determined by IIR using RECIST v1.1 within the first 4 months. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (<) 10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% confidence interval (CI) of ORR was calculated using the method of Clopper and Pearson. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 4

Interventionpercentage of participants (Number)
Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide15.0
Treatment Arm B: Ifosfamide + Etoposide7.3

ORR by IIR Assessment

ORR by IIR was defined as the percentage of participants with best overall response of CR or PR determined using RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to <10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% CI of ORR was calculated using the method of Clopper and Pearson. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: From the date of randomization to the date of the first documentation of CR or PR, whichever occurred first (up to approximately 14.2 months)

Interventionpercentage of participants (Number)
Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide15.0
Treatment Arm B: Ifosfamide + Etoposide9.8

Percentage of Participants With Overall Survival at 1 Year or Month 12 (OS-1y)

OS-1y was defined as the time from the date of randomization to the date of death from any cause assessed up to 1 year. OS was calculated using the Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 12 or 1 Year

Interventionpercentage of participants (Number)
Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide49.2
Treatment Arm B: Ifosfamide + Etoposide72.1

Percentage of Participants With PFS at 1 Year or Month 12 (PFS-1y Rate) by IIR Assessment

PFS-1y rate as assessed by IIR was defined as the percentage of participants who were alive and without PD at 1 year from randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS-1y rate was estimated using Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 12 or 1 Year

Interventionpercentage of participants (Number)
Treatment Arm A: Lenvatinib + Ifosfamide + EtoposideNA
Treatment Arm B: Ifosfamide + Etoposide14.9

Percentage of Participants With PFS at Month 4 (PFS-4m Rate) by IIR Assessment

PFS rate at 4 months as assessed by IIR was defined as the percentage of participants who were alive and without PD at 4 months from the randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. The PFS-4m was estimated using the Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 4

Interventionpercentage of participants (Number)
Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide76.3
Treatment Arm B: Ifosfamide + Etoposide66.0

Progression-free Survival (PFS) by Independent Imaging Review (IIR) Assessment

PFS as assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of PD or date of death (whichever occurred first), as determined using RECIST v1.1. PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method. (NCT04154189)
Timeframe: From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first (up to 14.2 months)

Interventionmonths (Median)
Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide6.5
Treatment Arm B: Ifosfamide + Etoposide5.5

Number of Participants Categorized Based on Overall Palatability and Acceptability Questionnaire Responses for Suspension of Lenvatinib

The palatability and acceptability of lenvatinib oral suspension formulation was assessed using the Palatability Questionnaire. In the questionnaire, participants were asked to answer palatability and acceptability of lenvatinib suspension considering the following elements: taste, appearance, smell, how does it feel in the mouth and overall acceptability in terms of 7 responses: Super good, really good, good, may be good or may be bad, bad, really bad, super bad. In this outcome measure, number of participants have been reported per their overall palatability and acceptability responses. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Cycle 1 Day 1 (Cycle length = 21 days)

InterventionParticipants (Count of Participants)
Super BadReally BadBadMay be Good or May be BadGoodReally GoodSuper Good
All Participants: Lenvatinib 14 mg/m^20002201

Treatment Arm A: Plasma Concentration of Lenvatinib

Plasma concentration of lenvatinib in participants from Treatment Arm A (Lenvatinib + Ifosfamide + Etoposide) at different time points were reported. As planned, data for this outcome measure was analyzed for treatment arm A only. Lenvatinib concentration in plasma was quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: Pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: Pre-dose (each Cycle length = 21 days)

Interventionnanograms per milliliter (ng/mL) (Mean)
Cycle 1, Day 1: 0.5-4 hours post-doseCycle 1, Day 1: 6-10 hours post-doseCycle 1, Day 15: Pre-doseCycle 1, Day 15: 0.5-4 hours post-doseCycle 1, Day 15: 6-10 hours post-doseCycle 2, Day 1: Pre-dose
Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide147.9217.870.7222.3310.970.2

Event-free Survival (EFS)

"EFS is defined as time from randomisation to the first of: death, detection of local recurrence or metastasis, progression of metastatic disease, or detection of a secondary malignancy.~EFS will be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals. Follow up per participant will be assessed for up to 10 years. The 3 year EFS is provided as a summary." (NCT00134030)
Timeframe: From date of randomization to date of the event.

InterventionPercentage EFS (Number)
MAP-GR74
MAPifn77
MAP-PR55
MAPIE53

Percentage of Patients With Overall Survival

"Overall survival is time from randomization until death from any cause.~Will be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals. Participants will be assessed for up to 10 years. 5 year overall survival is provided as a summary." (NCT00134030)
Timeframe: From date of randomization to date of death.

InterventionPercentage of participants (Number)
MAP-GR84
MAPifn84
MAP-PR68
MAPIE68

Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0

Percentages of patients experiencing grade 3 and 4 adverse events. These will be compared using chi-square tests or Fisher's exact tests where appropriate. (NCT00134030)
Timeframe: Adverse events are assessed for up to 10 years per participant.

InterventionParticipants (Count of Participants)
MAP-GR348
MAPifn340
MAP-PR287
MAPIE281

Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay

"A positive response to the tumor vaccine requires a positive reaction in at least one of the two assays below (immune responses to tumor lysates using ex vivo and delayed type of hypersensitivity (DTH).~The presence of a positive delayed type of hypersensitivity (DTH) reaction to the tumor lysate in a patient who did not show a positive DTH reaction prior to immunotherapy. A positive reaction is induration of at least 0.5 cm.~Immunotherapy administered to patients with recurrent or metastatic pediatric solid tumors such as Ewing's sarcoma, rhabdomyosarcoma, or neuroblastoma. Each vaccine is given as 6 separate injections. Three intradermal on one arm or leg and three subcutaneous on the other arm or leg." (NCT00923351)
Timeframe: Week 8, 14, 20 (Arm A) and on Days 42, 84 and 126 (± 7 days) (Arm B)

InterventionParticipants (Count of Participants)
Arm A - Participants Who Did Not Receive rhIL-70
Arm B - Participants Who Received rhIL-715

Overall Survival

Overall survival is defined as the time between the first day of treatment to the day of death. (NCT00923351)
Timeframe: Time between the first day of treatment to the day of death or at the conclusion of 5 years of follow-up, whichever comes first, assessed up to approximately 11 years.

Interventionyears (Median)
Arm A - Participants Who Did Not Receive rhIL-72.4
Arm B - Participants Who Received rhIL-74.3

Toxicity

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00923351)
Timeframe: Date treatment consent signed to date off study, approximately 49.5 months

InterventionParticipants (Count of Participants)
Arm A - Participants Who Did Not Receive rhIL-76
Arm B - Participants Who Received rhIL-724

Overall Survival

(NCT00802880)
Timeframe: Until completion of follow-up or patient death (estimated to be 1 year)

Interventionmonths (Median)
Dacarbazine8.09

Rate of Nausea/Emesis (Any Grade)

Approximately 18 weeks (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)

Interventionpercentage of participants (Number)
Dacarbazine22.5

Rate of Neutropenia (Grade 3/4)

"Grade 3 neutropenia = absolute neutrophil count of <1000 - 500/mm^3~Grade 4 neutropenia = absolute neutrophil count of <500/mm^3" (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)

Interventionpercentage of participants (Number)
Dacarbazine7.5

Time to Progression (TTP)

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Until completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Dacarbazine2.07

Best Anatomical Tumor Response

"Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker~Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal~Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal~Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions" (NCT00802880)
Timeframe: After completion of 3 cycles

Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Dacarbazine022230

Comparison of the SUV at up to 3 Tumor Sites

(NCT00802880)
Timeframe: Baseline and after every three cycles of treatment (up to 1 year)

Interventionstandard uptake value (Mean)
BaselineEnd of cycle 3End of cycle 6End of cycle 9End of cycle 12
Dacarbazine7.427.577.76.897.48

Correlate Overall Survival With Best Anatomic Response

(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial responseStable diseaseProgressive disease
Dacarbazine18.1614.777.96

Correlate Overall Survival With Best Metabolic Response

(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial metabolic responseStable metabolic diseaseProgressive metabolic disease
Dacarbazine18.1618.598.75

Correlate the Time to Progression With Best Anatomic Response

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial responseStable diseaseProgressive disease
DacarbazineNA4.141.97

Correlate the Tumor Metabolic Response Rate With the Tumor Anatomic Response Rate

(NCT00802880)
Timeframe: After completion of 3 cycles

,,,
Interventionparticipants (Number)
PRSDPDTotal
Partial Metabolic Response1214
Progressive Metabolic Disease182433
Stable Metabolic Disease010212
Total2202749

Correlate Time to Progression With Best Metabolic Response

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial metabolic responseStable metabolic diseaseProgressive metabolic disease
Dacarbazine3.955.302.07

Overall Disease Control Rate

(NCT00802880)
Timeframe: 12 months

Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Dacarbazine0051

Overall Tumor Metabolic Response

"Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.~Partial metabolic response (PMR)~Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.~Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within >50% of the lesions. No unequivocal new lesions.~Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.~Progressive metabolic disease (PMD):~Unequivocal development of one more new metabolically active lesions~Target lesion: 20% or greater increase in maximum SUV from baseline.~Non-target lesions: unequivocal increase in FDG activity" (NCT00802880)
Timeframe: After completion of 3 cycles

Interventionparticipants (Number)
CMRPMRSMDPMD
Dacarbazine041334

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.

InterventionParticipants (Count of Participants)
Cabozantinib53

Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas

Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.

Interventionpercentage of particpants (Number)
Cabozantinib11.1

Percentage of Participants With 6 Month Progression Free Survival (PFS)

Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT01755195)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Cabozantinib49.3

Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionpg/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib-51.3344.8

Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionng/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day1
Cabozantinib-6.116.4

Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionng/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib-1.0-10.9

Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionpg/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib5.632.5

Cluster of Differentiation 4 (CD4) Reconstitution

The median CD4 count with a range of 85-1565 (absolute count) was used to determine recovery and were considered recovered if in this range. The CD4 count was established by flow cytometry testing. (NCT00043979)
Timeframe: Day +28-42

Interventionmm(3) (Median)
Arm 2-Recipients284

Early Post Transplantation Relapse

Participants who experienced recurrence or progression of disease following transplant. (NCT00043979)
Timeframe: up to 300 days

InterventionDays (Median)
Arm 2-Recipients100

Median Progression Free Survival

Progression free survival was based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months

InterventionMonths (Median)
Arm 2-Recipients15.9

Median Time to Reach a Platelet Count of 50,000/mm(3)

Days for participants to achieve a platelet count of 50,000/mm(3). (NCT00043979)
Timeframe: up to 43 days

InterventionDays (Median)
Arm 2-Recipients15

Median Time to Reach Absolute Neutrophil Count of 500/mm(3)

Days for participants to achieve a neutrophil count of 500/mm(3). (NCT00043979)
Timeframe: up to 12 days

InterventionDays (Median)
Arm 2-Recipients9

Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)

GVT is defined as tumor response after day 42 post-transplantation without cytotoxic therapy. (NCT00043979)
Timeframe: up to day 100

InterventionParticipants (Count of Participants)
Arm 2-Recipients0

Number of Participants With Engraftment

Engraftment is defined as rapid conversion to complete donor chimerism and is assessed by blood counts and chimerism, >95% donor engraftment at day 100 in >75% of patients. (NCT00043979)
Timeframe: 100 days

InterventionParticipants (Number)
Arm 2-Recipients23

Toxicity

Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module. (NCT00043979)
Timeframe: 16.5 months

InterventionParticipants (Number)
Arm 2-Recipients30

Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)

Response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST). RECIST criteria offer a simplified, conservative, extraction of imaging data for wide application in clinical trials. They presume that linear measures are an adequate substitute for 2-D (dimensional) methods and registers four response categories: Complete response (CR) is disappearance of all target lesions. Partial response (PR) is 30% increase in the sum of the longest diameter of target lesions. Progressive disease (PD) is 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) is small changes that do not meet above criteria. For the purposes of this study very good partial response ((VGPR) is >75% reduction in disease) was also employed. (NCT00043979)
Timeframe: up to 10 cycles of therapy or 280 days

InterventionParticipants (Count of Participants)
Complete Response (CR)Progressive Disease (PD)Partial Response (PR)Very Good Partial Response (VGPR)
Arm 2-Recipients2442

Median Survival From Date of Progression

Median survival from date of progression is based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months

InterventionMonths (Median)
Participants who did not receive a transplant(n=7)Participants who received a transplant (n=23)
Arm 2-Recipients3.319.1

Number of Participants to Complete Conversion to >95% Donor Chimerism

Participants who tolerated the transplantation regimen and accepted >95% of the donors blood, marrow, and/or tissue. (NCT00043979)
Timeframe: up to 30 days

InterventionParticipants (Count of Participants)
Day +14Day +28
Arm 2-Recipients2323

Number of Participants With Acute and Chronic GVHD

Acute GVHD as by Modified Glucksberg Criteria occurring before day 100. Chronic GVHD as per Seattle criteria occurring after day 100. (NCT00043979)
Timeframe: up to 5 years or death

,
Interventionparticipants (Number)
acute GVHDchronic GVHD
Recipients -Cyclosporine GVHD Prophylaxis1212
Recipients -Tacrolimus/Sirolimus GVHD Prophylaxis55

Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy

Site of radiotherapy (high energy radiation) and/or toxicity experienced by the participants post HSCT radiotherapy. Grading was preformed using the Modified Glucksberg Criteria. (NCT00043979)
Timeframe: up to 6 cycles or 168 days

InterventionParticipants (Count of Participants)
Chest wall; G2 skinAbdomen; G4 GIPancreas; G4 LFTs, G4 pancreatitisPleura, mediastinum; G4 LFTs, G2 mucositisChest wall; G4 skin, G3 mucositisSpine, skull; G2 nausea+vomiting, G2 fatiguePelvis; G4 enteritisPulmonary (cyberknife)Brain; B3 mucositisWhole lung; G3 mucositis, G3 skin, G5 lungL arm, R shoulder, B/L femur
Arm 2-Recipients11111111111

Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant

Participants who are alive at two years following Allo-Hematopoietic Stem Cell Transplant. (NCT00043979)
Timeframe: 2 years

Interventionpercentage of participants (Number)
From date of enrollmentFrom date of transplantation
Arm 2-Recipients39.134.8

Reviews

52 reviews available for ifosfamide and Bone Neoplasms

ArticleYear
Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature.
    Journal of medical case reports, 2022, Jun-28, Volume: 16, Issue:1

    Topics: Bone Neoplasms; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Second Primary; Osteosa

2022
Clinical characteristics of primary cutaneous and subcutaneous Ewing sarcoma.
    Japanese journal of clinical oncology, 2023, Jun-29, Volume: 53, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo

2023
Primary Ewing sarcoma of the larynx with distant metastasis: a case report and review of the literature.
    Current oncology (Toronto, Ont.), 2019, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Bone Neoplasms; Chemoradiotherapy; Cyclophosphamide; Dactinomycin; Etoposide;

2019
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.
    Journal of orthopaedic surgery and research, 2020, Feb-13, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Do

2020
Unusual aggressive breast cancer: metastatic malignant phyllodes tumor.
    Journal of radiology case reports, 2013, Volume: 7, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidi

2013
Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
    Clinical therapeutics, 2014, Apr-01, Volume: 36, Issue:4

    Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2014
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Cohort

2014
Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma.
    Advances in experimental medicine and biology, 2014, Volume: 804

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C

2014
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
    Paediatric drugs, 2014, Volume: 16, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Doc

2014
Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Ifosfamide; Neoadjuvant Ther

2015
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2015, Sep-30, Issue:9

    Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid

2015
An update on chemotherapy for osteosarcoma.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:18

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Clinical Tri

2015
Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Humans; Ifosf

2015
Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing's Sarcoma Treatment: A Network Meta-Analysis.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Etoposide; Fe

2018
Leiomyosarcoma of the parotid gland in an HIV-positive patient: therapeutic approach, clinical course and review of the literature.
    Journal of chemotherapy (Florence, Italy), 2009, Volume: 21, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biomar

2009
Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
    IDrugs : the investigational drugs journal, 2010, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinic

2010
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2010, Feb-17, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamide; Sarc

2010
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
    The Lancet. Oncology, 2010, Volume: 11, Issue:7

    Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; H

2010
[Clinical characteristics and treatment of desmoplastic small round cell tumor].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2

    Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas

2010
Leiomyosarcoma of the tongue with multiple metastases: a case report and review of literature.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:7

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2012
Isolated subcutaneous metastasis of osteosarcoma 5 years after initial diagnosis.
    Journal of pediatric surgery, 2011, Volume: 46, Issue:10

    Topics: Abdominal Wall; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas

2011
The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C

2012
Advanced therapeutic strategy for radiation-induced osteosarcoma in the skull base: a case report and review.
    Radiation oncology (London, England), 2012, Aug-10, Volume: 7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality T

2012
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2012, Dec-12, Volume: 12

    Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid

2012
Small cell carcinoma of the bladder: a case report and a literature review.
    Archivos espanoles de urologia, 2003, Volume: 56, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Small Cell;

2003
Ifosfamide in pediatric solid tumors.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf

2003
Palliative treatment for advanced or metastatic osteosarcoma.
    The Israel Medical Association journal : IMAJ, 2004, Volume: 6, Issue:1

    Topics: Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A

2004
Osteosarcoma occurring in osteogenesis imperfecta.
    Virchows Archiv : an international journal of pathology, 2004, Volume: 444, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality

2004
[Soft tissue sarcoma: postoperative chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

2004
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin;

2004
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

2005
Anaplastic large cell lymphoma of bone--is it a bad tumor?
    Pediatric blood & cancer, 2007, Volume: 48, Issue:4

    Topics: Activin Receptors, Type II; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2007
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Mo

2005
Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
    Future oncology (London, England), 2006, Volume: 2, Issue:3

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; H

2006
[Neoadjuvant treatment in osteosarcomas].
    Bulletin du cancer, 2006, Volume: 93, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D

2006
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.
    Current opinion in oncology, 2007, Volume: 19, Issue:4

    Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemotherapy, Adjuvant;

2007
[Clinical features of patients with metastasis in phalanges as first symptom of primary lung cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcino

2007
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
    Hematology/oncology clinics of North America, 1995, Volume: 9, Issue:4

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoth

1995
Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS).
    Cancer treatment and research, 1993, Volume: 62

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemotherapy, Adjuvant; C

1993
An update of Scandinavian studies of osteosarcoma.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla

1993
Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Th

1993
Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child

1993
Results of therapy in osteosarcoma: experience in childrens hospitals in Buenos Aires.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Neoplasms; Chemotherapy, Adjuvant; C

1993
An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Acidosis, Renal Tubular; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap

1993
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Acetylcysteine; Bone Neoplasms; Fluid Therapy; Humans; Ifosfamide; Mesna; Randomized Controlled Tria

1993
High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C

1996
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-01, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neopl

2001
Adult Gaucher disease in association with primary malignant bone tumors.
    Cancer, 2001, Feb-01, Volume: 91, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Cyclophosphamide;

2001
Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
    Cancer, 2001, Sep-15, Volume: 92, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Combined Mo

2001
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma;

1992
Chemotherapy of advanced sarcomas of bone and soft tissue.
    Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin

1992
Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry.
    Clinical orthopaedics and related research, 1991, Issue:270

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Austria; Bleomycin; Bone Neoplasm

1991

Trials

112 trials available for ifosfamide and Bone Neoplasms

ArticleYear
Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France.
    International journal of cancer, 2023, 04-15, Volume: 152, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactin

2023
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph

2022
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph

2022
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph

2022
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph

2022
Long-Term Outcomes in Patients With Localized Ewing Sarcoma Treated With Interval-Compressed Chemotherapy on Children's Oncology Group Study AEWS0031.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-20, Volume: 41, Issue:30

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Doxorubicin; Etoposide; Human

2023
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
    Trials, 2020, Jan-17, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents;

2020
Extraskeletal Ewing sarcoma in children, adolescents, and young adults. An analysis of three prospective studies of the Cooperative Weichteilsarkomstudiengruppe (CWS).
    Pediatric blood & cancer, 2021, Volume: 68, Issue:10

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide;

2021
OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.
    Future oncology (London, England), 2021, Volume: 17, Issue:32

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Etoposide;

2021
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
    Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Female; Follow-U

2017
Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
    Medical oncology (Northwood, London, England), 2017, Nov-01, Volume: 34, Issue:12

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

2017
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 88

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2018
Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression.
    European review for medical and pharmacological sciences, 2018, Volume: 22, Issue:19

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms

2018
Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
    International journal of cancer, 2020, 01-15, Volume: 146, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin;

2020
Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
    Journal of chemotherapy (Florence, Italy), 2013, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

2013
Treatment of large osteosarcoma in children: new approach.
    Experimental oncology, 2013, Volume: 35, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Doxoru

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.
    Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:1

    Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil

2014
High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2014
Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Aug-10, Volume: 32, Issue:23

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Consolidation Chemotherapy; C

2014
Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Annals of surgical oncology, 2015, Volume: 22, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

2015
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin

2015
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin

2015
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin

2015
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin

2015
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherap

2014
Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival;

2015
Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:10

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brazil; Carboplatin; Chi

2015
Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:16

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone

2015
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Journal of surgical oncology, 2015, Volume: 112, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-Response

2015
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud

2016
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud

2016
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud

2016
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud

2016
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Sep-20, Volume: 26, Issue:27

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
    Annals of nuclear medicine, 2009, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone

2009
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-20, Volume: 27, Issue:15

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

2009
Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
    Journal of chemotherapy (Florence, Italy), 2009, Volume: 21, Issue:2

    Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil

2009
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
    Anticancer research, 2009, Volume: 29, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality

2009
Results of RS-99 protocol for childhood solid tumors.
    World journal of pediatrics : WJP, 2010, Volume: 6, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant;

2010
[Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin].
    Voprosy onkologii, 2010, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chem

2010
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child;

2011
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
    Cancer, 2011, Jun-15, Volume: 117, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil

2011
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-10, Volume: 30, Issue:17

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

2012
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-20, Volume: 30, Issue:33

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2012
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-20, Volume: 30, Issue:33

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2012
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-20, Volume: 30, Issue:33

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2012
Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-20, Volume: 30, Issue:33

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2012
A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).
    Journal of experimental & clinical cancer research : CR, 2002, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease Progression; Dose-R

2002
Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
    American journal of clinical oncology, 2002, Volume: 25, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Histi

2002
Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
    The New England journal of medicine, 2003, Feb-20, Volume: 348, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp

2003
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child; Child

2003
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-15, Volume: 21, Issue:18

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2003
Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
    Cancer, 2004, Feb-15, Volume: 100, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap

2004
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
    Cancer, 2004, Apr-15, Volume: 100, Issue:8

    Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Bone Neoplasms; Child; Child, Presc

2004
A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
    Cancer, 2004, Jul-01, Volume: 101, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diseas

2004
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2004
High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Experimental oncology, 2004, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival;

2004
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:2

    Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bo

2005
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols

2005
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols

2005
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols

2005
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols

2005
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carbo

2005
A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
    Pediatric blood & cancer, 2006, Volume: 46, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl

2006
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2005
Metastatic osteosarcoma.
    Cancer, 2006, Jan-15, Volume: 106, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil

2006
Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-01, Volume: 24, Issue:7

    Topics: Adolescent; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Br

2006
High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experie
    Cancer, 2006, Apr-15, Volume: 106, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child; Chil

2006
Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
    Cancer, 2006, Apr-15, Volume: 106, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M

2006
Local control in pelvic Ewing sarcoma: analysis from INT-0091--a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child

2006
Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group.
    Blood, 2007, Jan-01, Volume: 109, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Ch

2007
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2007
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2007
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2007
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2007
Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-20, Volume: 25, Issue:21

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon

2007
A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.
    Oncology, 2007, Volume: 72, Issue:3-4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Epirub

2007
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2008
[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
    Nowotwory, 1981, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Clinical Trials a

1981
Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial.
    International journal of radiation oncology, biology, physics, 1995, Jul-15, Volume: 32, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M

1995
Salvage chemotherapy for recurrent Ewing's sarcomas.
    Neoplasma, 1995, Volume: 42, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide;

1995
Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemot

1993
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
    Cancer investigation, 1995, Volume: 13, Issue:3

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms

1995
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

1995
An update of Scandinavian studies of osteosarcoma.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla

1993
Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Th

1993
Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child

1993
Results of therapy in osteosarcoma: experience in childrens hospitals in Buenos Aires.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Neoplasms; Chemotherapy, Adjuvant; C

1993
No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
    Journal of chemotherapy (Florence, Italy), 1993, Volume: 5, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.
    American journal of clinical oncology, 1996, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined

1996
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
    Cancer, 1996, Aug-15, Volume: 78, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp

1996
Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study.
    Journal of chemotherapy (Florence, Italy), 1996, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxoru

1996
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Neoplasms; C

1997
Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Etoposide;

1997
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dose-Response Relationsh

1997
Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
    Breast cancer research and treatment, 1997, Volume: 45, Issue:1

    Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; F

1997
Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy

1997
Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
    Cancer, 1998, Mar-15, Volume: 82, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

1998
Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chem

1998
Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
    Pediatric nephrology (Berlin, Germany), 1998, Volume: 12, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

1998
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon

1998
Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child, Presc

1998
Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

1998
Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combined Mo

1998
Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

1998
Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92.
    International journal of radiation oncology, biology, physics, 1998, Dec-01, Volume: 42, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

1998
Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

1998
Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study.
    Medical and pediatric oncology, 1999, Volume: 32, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

1999
Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Anti-cancer drugs, 1999, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

1999
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

1999
WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:6

    Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Neo

1999
High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société F
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

1999
Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2000, Volume: 8, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone

2000
Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil

2000
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Cancer, 2000, May-01, Volume: 88, Issue:9

    Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chi-Square Distribu

2000
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

2000
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2001, Volume: 27, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant;

2001
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr

2002
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2001
High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chondrocytes; Cis

2002
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma;

1992
Effect of chemotherapy combined with caffeine for osteosarcoma.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Calcane

1992
BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Brain Neoplasms; Chorioni

1991
Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry.
    Clinical orthopaedics and related research, 1991, Issue:270

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Austria; Bleomycin; Bone Neoplasm

1991
Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).
    Cancer, 1990, Oct-15, Volume: 66, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda

1990
Intensified chemotherapy with ifosfamide (IFO) and influence of intraarterial (i.a.) versus intravenous (i.v.) infusion of cisplatinum (DDP). Preliminary results.
    La Chirurgia degli organi di movimento, 1990, Volume: 75, Issue:1 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Humans; Ifosfamide; Infus

1990
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:9

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bra

1989
Initial chemotherapy including ifosfamide in the management of Ewing's sarcoma: preliminary results. A protocol of the French Pediatric Oncology Society (SFOP).
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

1989

Other Studies

255 other studies available for ifosfamide and Bone Neoplasms

ArticleYear
A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma.
    Current oncology (Toronto, Ont.), 2021, 12-12, Volume: 28, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Humans; Ifosfamide; Os

2021
Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
    Japanese journal of clinical oncology, 2022, May-31, Volume: 52, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Humans; Ifosfamid

2022
Outcomes of Pediatric Patients With Metastatic Ewing Sarcoma Treated With Interval Compression.
    Journal of pediatric hematology/oncology, 2023, 04-01, Volume: 45, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

2023
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
    Cancer, 2022, 08-01, Volume: 128, Issue:15

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms;

2022
Dual enzyme therapy improves adherence to chemotherapy in a patient with gaucher disease and Ewing sarcoma.
    Pediatric hematology and oncology, 2023, Volume: 40, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide;

2023
Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS).
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 176

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cause of Death; Cisplati

2022
Successful Treatment of Patient With Ewing Sarcoma in the Setting of Inherited Cholestatic Liver Disease.
    Journal of pediatric hematology/oncology, 2023, Jul-01, Volume: 45, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cholestasis; Cholestasis, Intrahepat

2023
Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study.
    Journal of cancer research and therapeutics, 2023, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Heterografts

2023
Outcomes and survival rates of childhood osteosarcoma in Iran, A report from MAHAK Pediatric Cancer Treatment and Research Center, from 2007 to 2020.
    Journal of cancer research and therapeutics, 2023, Volume: 19, Issue:Supplement

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

2023
Total Neoadjuvant vs. Standard Perioperative Cisplatin/ Doxorubicin Chemotherapy in Patients with Extremities Osteosarcoma: A Multi-Center Cohort Study.
    Asian Pacific journal of cancer prevention : APJCP, 2023, Jul-01, Volume: 24, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Extremities;

2023
Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

2020
Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
    BMC cancer, 2019, Dec-02, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

2019
Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide.
    The oncologist, 2020, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp

2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and
    Cancer, 2020, 06-01, Volume: 126, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Dacarbazine; Doxorubicin; Female; Humans; Ifosfamide

2020
Challenges in the management of localized Ewing sarcoma in a developing country.
    Pediatric hematology and oncology, 2020, Volume: 37, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

2020
Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis.
    The Journal of international medical research, 2020, Volume: 48, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chin

2020
IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
    Journal of pediatric hematology/oncology, 2021, 05-01, Volume: 43, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Cost-B

2021
Ifosfamide induced encephalopathy in a child with osteosarcoma.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:5

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Female; Humans; Ifosf

2021
A Case of Ewing Sarcoma of the Bladder Presenting in Early Infancy.
    Journal of pediatric hematology/oncology, 2021, 05-01, Volume: 43, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etopo

2021
Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing country.
    Pediatric blood & cancer, 2021, Volume: 68, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide;

2021
Chronic kidney disease consecutive to chemotherapy for chondroblastic osteosarcoma: A report on 6 pediatric cases.
    Nephrologie & therapeutique, 2021, Volume: 17, Issue:7

    Topics: Adolescent; Bone Neoplasms; Child; Humans; Ifosfamide; Osteosarcoma; Renal Insufficiency, Chronic; R

2021
Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group.
    Japanese journal of clinical oncology, 2021, Oct-05, Volume: 51, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D

2021
Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
    Journal of surgical oncology, 2017, Volume: 115, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D

2017
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-10, Volume: 35, Issue:20

    Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla

2017
Transition from Tumor Tissue to Bone Marrow in Patients with Appendicular Osteosarcoma after Neoadjuvant Chemotherapy.
    Chinese medical journal, 2017, Sep-20, Volume: 130, Issue:18

    Topics: Adolescent; Adult; Bone Marrow; Bone Neoplasms; Child; Cisplatin; Doxorubicin; Female; Humans; Ifosf

2017
Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 85

    Topics: Adolescent; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms;

2017
Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.
    International journal of radiation oncology, biology, physics, 2017, 12-01, Volume: 99, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2017
Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases.
    Fundamental & clinical pharmacology, 2018, Volume: 32, Issue:3

    Topics: Administration, Intravenous; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Di

2018
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.
    Medicine, 2017, Volume: 96, Issue:51

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Endostatins; Etoposide; Human

2017
Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation.
    Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cardiotoxicity; Dimethyl Sulf

2019
Curettage, phenolization, and cementation in paediatric Ewing's sarcoma with a complete radiological response to neoadjuvant chemotherapy.
    International orthopaedics, 2019, Volume: 43, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Case-

2019
Mesenchymal chondrosarcoma metastasising to the pancreas.
    BMJ case reports, 2018, Dec-31, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cholangiopan

2018
Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma.
    International journal of clinical oncology, 2019, Volume: 24, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant;

2019
Osteosarcoma journey over two decades in India: Small steps, big changes.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

2019
Metastasis of osteosarcoma to stomach made clinically evident by hematemesis: a case report.
    World journal of surgical oncology, 2013, Feb-26, Volume: 11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Combin

2013
Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions.
    American journal of clinical oncology, 2014, Volume: 37, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp

2014
Osteosarcoma around the knee treated with neoadjuvant chemotherapy and a custom-designed prosthesis.
    Orthopedics, 2013, Volume: 36, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arthroplasty, Replacement, Knee;

2013
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:2

    Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla

2013
Metastatic malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): results with PNET-based chemotherapy.
    American journal of clinical oncology, 2015, Volume: 38, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin

2015
Ifosfamide induced renal rickets.
    Indian journal of pediatrics, 2014, Volume: 81, Issue:9

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child, Preschool; Chronic Kidney Disease-Mineral

2014
Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.
    Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2014, Volume: 17, Issue:1

    Topics: Acute Kidney Injury; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Hemodiaf

2014
Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?
    Clinical orthopaedics and related research, 2014, Volume: 472, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Dedifferenti

2014
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Female; Hearing Loss; Huma

2014
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp

2013
[Value of ifosfamide in neoadjuvant therapy for osteosarcoma].
    Der Orthopade, 2013, Volume: 42, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D

2013
Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-R

2014
Validation of a multi-modal treatment protocol for Ewing sarcoma--a report from the polish pediatric oncology group.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2014
Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency.
    Annals of surgical oncology, 2015, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms

2015
Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes.
    World journal of surgical oncology, 2014, Nov-11, Volume: 12

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant;

2014
Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

2015
Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
    Toxicology letters, 2015, Jan-05, Volume: 232, Issue:1

    Topics: Activation, Metabolic; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Line, Tumor; Cell Sur

2015
Ifosfamide-containing regimens for treating patients with osteosarcomas.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Epirubicin; F

2014
Developing a prognostic model for localized Ewing sarcoma family of tumors: A single institutional experience of 224 cases treated with uniform chemotherapy protocol.
    Journal of surgical oncology, 2015, Volume: 111, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant;

2015
Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
    Histopathology, 2015, Volume: 67, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfam

2015
Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles.
    Oncology reports, 2015, Volume: 33, Issue:4

    Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Bone

2015
Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; China; Dox

2015
First evidence of treatment efficacy in metastatic carcinoma of the parotid gland with BRD4/NUT translocation.
    Journal of chemotherapy (Florence, Italy), 2016, Volume: 28, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Cisplatin; Doxorub

2016
A trimodality approach in the management of metastatic low-grade epithelioid hemangioendothelioma of the bone.
    BMJ case reports, 2015, Jul-16, Volume: 2015

    Topics: Adult; Antineoplastic Agents; Bone Nails; Bone Neoplasms; Doxorubicin; Femur; Foot; Fracture Fixatio

2015
Identification of Discrete Prognostic Groups in Ewing Sarcoma.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:1

    Topics: Adolescent; Adult; Age Factors; Bone Neoplasms; Child; Child, Preschool; Databases, Factual; Etoposi

2016
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin

2015
Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cardiotonic Agents; Chil

2016
Treatment of Patients with Distant Metastases from Phyllodes Tumor of the Breast.
    World journal of surgery, 2016, Volume: 40, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neopla

2016
Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.
    BMC cancer, 2015, Oct-21, Volume: 15

    Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Bone Neoplasms; Caspase 3; Cell Line, Tumor;

2015
Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; Doxorubicin

2016
Ewing Sarcoma: A 15-Year Experience of a Single Center With the MSKCC P6 Treatment Protocol.
    Journal of pediatric hematology/oncology, 2016, Volume: 38, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

2016
Singapore Cancer Network (SCAN) Guidelines for the Initial Evaluation, Diagnosis, and Management of Extremity Soft Tissue Sarcoma and Osteosarcoma.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Chemotherapy, Adjuvan

2015
Marriage and fertility in long-term survivors of childhood, adolescent and young adult (AYA) high-grade sarcoma.
    International journal of clinical oncology, 2016, Volume: 21, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

2016
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
    Pediatric nephrology (Berlin, Germany), 2016, Volume: 31, Issue:6

    Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro

2016
Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Chi

2016
A Pediatric Case of Metastatic Conventional Parosteal Osteosarcoma Treated With Multidrug Chemotherapy.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cispla

2016
Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.
    Cancer biology & therapy, 2016, 10-02, Volume: 17, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Bone Neoplasms; BRCA2 Protein; Dioxol

2016
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
    Oncotarget, 2016, Sep-20, Volume: 7, Issue:38

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms

2016
Osteosarcoma: the same old drugs or more?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-20, Volume: 26, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifos

2008
Osteosarcoma in a patient with xeroderma pigmentosum.
    Joint bone spine, 2009, Volume: 76, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2009
Pleomorphic malignant fibrous histiocytoma: response of bone, lung, and brain metastases to chemotherapy.
    Radiation medicine, 2008, Volume: 26, Issue:8

    Topics: Acetabulum; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Brain; B

2008
Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.
    Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality

2009
Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2009, Volume: 14, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neopla

2009
Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma.
    Anti-cancer drugs, 2009, Volume: 20, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas

2009
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
    Leukemia research, 2009, Volume: 33, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Co

2009
Extra-osseous Ewing sarcoma.
    Pediatric hematology and oncology, 2009, Volume: 26, Issue:4

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Ch

2009
Local and systemic control of Ewing's bone sarcoma family tumors of the ribs.
    Journal of surgical oncology, 2009, Sep-01, Volume: 100, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Plates; Chil

2009
An osteoporotic hip fracture in a 14-year-old girl undergoing chemotherapy and operated for knee osteosarcoma.
    Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology, 2009, Volume: 10, Issue:3

    Topics: Adolescent; Antineoplastic Agents; Arthroplasty, Replacement, Knee; Bone Neoplasms; Chemotherapy, Ad

2009
Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2009, Volume: 185 Suppl 2

    Topics: Adolescent; Aftercare; Antineoplastic Combined Chemotherapy Protocols; Austria; Bone Neoplasms; Card

2009
Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2009, Volume: 185 Suppl 2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Chemotherapy,

2009
Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2009, Volume: 30, Issue:4

    Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Disease Progression; Female; Ifosfamide; Immunotherapy; I

2009
Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Dec-01, Volume: 15, Issue:23

    Topics: Animals; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor

2009
Ifosfamide-induced encephalopathy and movement disorder.
    Pediatric blood & cancer, 2010, Volume: 54, Issue:4

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Child; Female; Humans

2010
Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2010, Volume: 15, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cisplatin; Dose-R

2010
Metastatic primary angiosarcoma of the breast in a pediatric patient with a complete response to systemic chemotherapy and definitive radiation therapy: case report and review of the literature.
    Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combin

2010
Outcome analysis of patients with transformed teratoma to primitive neuroectodermal tumor.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosph

2010
Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis.
    Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Membe

2010
Moyamoya in a child treated with interferon for recurrent osteosarcoma.
    Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:6

    Topics: Antineoplastic Agents; Bone Neoplasms; Carotid Artery Diseases; Cerebral Arterial Diseases; Cerebral

2010
Pulmonary blastoma in adult: dramatic but transient response to doxorubicin plus ifosfamide.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Administration Sch

2011
Chest wall Ewing sarcoma family of tumors: long-term outcomes.
    International journal of radiation oncology, biology, physics, 2011, Sep-01, Volume: 81, Issue:1

    Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla

2011
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
    Cancer research, 2010, Oct-01, Volume: 70, Issue:19

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor

2010
Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response.
    International journal of cancer, 2011, Aug-01, Volume: 129, Issue:3

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Disease Models, Animal

2011
Neuroblastoma in an adult: case report.
    Revista medica de Chile, 2010, Volume: 138, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Brain Neoplasms; Carboplatin

2010
Magnetic resonance imaging is appropriate for determining the osteotomy plane for appendicular osteosarcoma after neoadjuvant chemotherapy.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

2012
Treatment outcome of Korean patients with localized Ewing sarcoma family of tumors: a single institution experience.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:6

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleom

2011
Relationship between hypermethylated MGMT gene and osteosarcoma necrosis rate after chemotherapy.
    Pathology oncology research : POR, 2011, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

2011
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.
    Acta orthopaedica, 2011, Volume: 82, Issue:2

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemo

2011
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2011
Unusual seminoma revealed by bone metastasis.
    Joint bone spine, 2011, Volume: 78, Issue:6

    Topics: Bone Neoplasms; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Ifosfamide; Magnetic Resona

2011
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human

2011
Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
    Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2011
Extraskeletal osteosarcoma of the breast in an adolescent girl.
    Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemot

2012
Small cell osteosarcoma successfully treated by high-dose ifosfamide and methotrexate, combined with carboplatin and pirarubicin.
    Anticancer research, 2012, Volume: 32, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherapy, Adjuvant;

2012
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
    International journal of clinical oncology, 2013, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytid

2013
Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jun-10, Volume: 30, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D

2012
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl

2012
[Organ-preserving interventions in combined therapy of children and adolescents with osteosarcoma].
    Voprosy onkologii, 2012, Volume: 58, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Transplantation; Ch

2012
Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy.
    Asia-Pacific journal of clinical oncology, 2013, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasm

2013
Ifosfamide and doxorubicin combination chemotherapy for recurrent nasopharyngeal carcinoma patients.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamo

2012
Regression of mesenchymal hamartoma of the liver with sarcoma chemotherapy.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomyci

2013
Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma.
    Veterinary and comparative oncology, 2014, Volume: 12, Issue:4

    Topics: Amputation, Surgical; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera

2014
The Effects of N-acetylcysteine on ifosfamide efficacy in a mouse xenograft model.
    Anticancer research, 2012, Volume: 32, Issue:9

    Topics: Acetylcysteine; Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Growth Processes; C

2012
Case report: stimulation of puberty in a girl with chemo- and radiation therapy induced ovarian failure by transplantation of a small part of her frozen/thawed ovarian tissue.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cryopreservation; Cyclophosphamide;

2013
[Treatment and prognosis of stage IV alveolar soft part sarcoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Dacarbazine;

2012
Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years.
    Tumori, 2012, Volume: 98, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

2012
High-dose chemotherapy and autologous peripheral blood stem-cell transfusion after conventional chemotherapy for patients with high-risk Ewing's tumors.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2002, Volume: 7, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil

2002
Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide.
    Oncogene, 2002, Oct-31, Volume: 21, Issue:50

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
    The oncologist, 2002, Volume: 7, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diph

2002
A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; C

2002
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Feb-01, Volume: 21, Issue:3

    Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arm; ATP Binding Cassette T

2003
Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
    Journal of pediatric hematology/oncology, 2003, Volume: 25, Issue:4

    Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Co

2003
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil

2003
Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.
    Oncology, 2003, Volume: 65, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp

2003
Ileoileal intussusception caused by a Ewing sarcoma tumour. An unusual case report.
    European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie, 2003, Volume: 13, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda

2003
Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
    Pediatric hematology and oncology, 2003, Volume: 20, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-Response

2003
Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-15, Volume: 21, Issue:24

    Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Humans; Ifosfa

2003
Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2004, Volume: 12, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoprevention; Female; Huma

2004
Methylene blue reversal of ifosfamide-related encephalopathy.
    Journal of pediatric hematology/oncology, 2004, Volume: 26, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Electroencephalography; Enzyme Inhibitors;

2004
[Neoadjuvant chemotherapy for osteosarcoma].
    Zhonghua yi xue za zhi, 2004, Jul-17, Volume: 84, Issue:14

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

2004
Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors.
    International journal of radiation oncology, biology, physics, 2004, Nov-01, Volume: 60, Issue:3

    Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil

2004
Spinal cord compression and lung metastasis of Wilms' tumor in a pregnant adolescent.
    Urology, 2004, Volume: 64, Issue:4

    Topics: Abdominal Pain; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbopla

2004
[Goal and results of the COSS study].
    Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V..., 2004, Volume: 36, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy

2004
High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
    Pediatric blood & cancer, 2005, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Hu

2005
VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors.
    American journal of clinical oncology, 2004, Volume: 27, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug R

2004
Ewing's sarcoma of the axial system in patients older than 15 years: dismal prognosis despite intensive multiagent chemotherapy and aggressive local treatment.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide;

2004
Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child, Preschool; Cispl

2005
[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp

2005
The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery.
    International journal of radiation oncology, biology, physics, 2005, Jul-01, Volume: 62, Issue:3

    Topics: Adolescent; Adult; Aged; Amputation, Surgical; Analysis of Variance; Antineoplastic Combined Chemoth

2005
The effect of multidrug chemotherapy on bone graft augmented prosthesis fixation.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2005, Volume: 23, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che

2005
Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
    Anti-cancer drugs, 2005, Volume: 16, Issue:7

    Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas

2005
Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era.
    International journal of radiation oncology, biology, physics, 2006, Feb-01, Volume: 64, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2006
Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
    Pediatric blood & cancer, 2006, Volume: 47, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2006
Fas expression in lung metastasis from osteosarcoma patients.
    Journal of pediatric hematology/oncology, 2005, Volume: 27, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2005
Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
    Cancer, 2006, Mar-15, Volume: 106, Issue:6

    Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Combined Mod

2006
Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
    Pediatric blood & cancer, 2006, Volume: 47, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Clinical T

2006
Sacral epithelioid angiosarcoma associated with a bleeding diathesis and spinal epidural hematoma: case report.
    Journal of neurosurgery. Spine, 2006, Volume: 4, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Neoplasms; Combined M

2006
Malignant mixed Mullerian tumors.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemo

2006
Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma.
    Pediatric blood & cancer, 2007, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

2007
Clearance of methotrexate by means of hemofiltration in a patient with osteosarcoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:5

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplati

2006
[Acquired Fanconi-de Toni-Debre syndrome due to therapy for Ewing's sarcoma in 5-years old boy].
    Przeglad lekarski, 2006, Volume: 63 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child, Preschool; Dactinomycin; Doxo

2006
Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
    International journal of radiation oncology, biology, physics, 2007, Feb-01, Volume: 67, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

2007
Primary rhabdomyosarcoma of the breast in a 13-year-old girl: report of a case.
    Surgery today, 2007, Volume: 37, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dactin

2007
Juvenile Ewing sarcoma presenting as a pelvic mass.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2007, Volume: 17, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therap

2007
Clinical outcome of patients with Ewing sarcoma family of tumors of bone in Japan: the Japanese Musculoskeletal Oncology Group cooperative study.
    Cancer, 2007, Feb-15, Volume: 109, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasms; Chi

2007
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
    Pediatric blood & cancer, 2007, Volume: 49, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined

2007
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:3

    Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles

2007
Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde.
    Anti-cancer drugs, 2007, Volume: 18, Issue:5

    Topics: Acetaldehyde; Adenosine Triphosphate; Annexin A5; Antineoplastic Agents, Alkylating; Blotting, Weste

2007
Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors.
    Pediatric blood & cancer, 2007, Volume: 49, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined M

2007
Ewing's sarcoma and primitive neuroectodermal tumour in adults: single-centre experience in The Netherlands.
    The Netherlands journal of medicine, 2007, Volume: 65, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality

2007
Acute pancreatitis associated with ifosfamide.
    Journal of the Chinese Medical Association : JCMA, 2007, Volume: 70, Issue:4

    Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Humans; Ifosfamide; Male; O

2007
Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999.
    Acta orthopaedica, 2007, Volume: 78, Issue:3

    Topics: Adult; Amputation, Surgical; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Bone Ne

2007
Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma.
    Clinical orthopaedics and related research, 2007, Volume: 462

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combin

2007
Prognostic factors for local and distant control in Ewing sarcoma family of tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Child, Pres

2008
[Preoperative adjuvant therapy for primary malignant bone tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomycin; Doxo

2007
F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Clinical nuclear medicine, 2008, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Fluorodeoxyglucose F18

2008
Multimodality treatment of osteosarcoma: radiation in a high-risk cohort.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

2008
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
    Gan no rinsho. Japan journal of cancer clinics, 1984, Volume: 30, Issue:9 Suppl

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide;

1984
[Cytostatic treatment of hypernephroid renal carcinoma (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1980, Dec-26, Volume: 105, Issue:52

    Topics: Adenocarcinoma; Bone Neoplasms; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Neoplasms; Lung

1980
Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
    Medical and pediatric oncology, 1996, Volume: 26, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood; Bone Marrow; Bone Neopl

1996
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.
    Lancet (London, England), 1994, Mar-26, Volume: 343, Issue:8900

    Topics: Administration, Oral; Adolescent; Antidotes; Bone Neoplasms; Brain Diseases; Drug Overdose; Female;

1994
Osteosarcoma following radiation treatment for meningioma: report of a case and effective treatment with chemotherapy.
    Journal of neuro-oncology, 1994, Volume: 21, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Dacti

1994
Ifosfamide-induced Fanconi syndrome.
    The Annals of pharmacotherapy, 1995, Volume: 29, Issue:6

    Topics: Adult; Bone Neoplasms; Fanconi Syndrome; Humans; Ifosfamide; Male; Osteomalacia; Osteosarcoma

1995
A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery.
    Cancer treatment and research, 1993, Volume: 62

    Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bo

1993
Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:12

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

1994
Acute pancreatitis after ifosfamide therapy.
    Cancer, 1994, Sep-01, Volume: 74, Issue:5

    Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; H

1994
Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats.
    Cancer research, 1994, Apr-01, Volume: 54, Issue:7

    Topics: Animals; Bone Neoplasms; Cell Line; Doxorubicin; Female; Femur; Ifosfamide; Male; Melanoma, Amelanot

1994
Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1993, Volume: 169, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

1993
Wernicke-encephalopathy in children with cancer.
    Medical and pediatric oncology, 1994, Volume: 22, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda

1994
Long-term disease-free survival in a child with refractory metastatic malignant germ cell tumor treated by high-dose chemotherapy with autologous bone marrow rescues.
    Medical and pediatric oncology, 1994, Volume: 22, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Cisplat

1994
[Ifosfamide in combined hormonochemotherapy on prostate cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:2

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone

1994
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:4

    Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo

1993
Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide.
    Cancer, 1993, Apr-15, Volume: 71, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child; Chil

1993
Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone

1993
Case report: pulmonary blastoma in children--response to chemotherapy.
    Medical and pediatric oncology, 1996, Volume: 26, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda

1996
Intense gallbladder uptake associated with chemotherapy. An unusual finding in pediatric skeletal scintigraphy.
    Clinical nuclear medicine, 1995, Volume: 20, Issue:11

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; B

1995
True histiocytic lymphoma following therapy for lymphoblastic neoplasms.
    Blood, 1996, Jun-15, Volume: 87, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Neoplasms; Child; Cisplati

1996
[Neoadjuvant treatment of Ewing's sarcoma: results obtained in 122 patients treated with a 6-drug chemotherapeutic protocol (vincristine, adriamycin, cyclophosphamide, dactinomycin, ifosfamide and etoposide)].
    Minerva pediatrica, 1995, Volume: 47, Issue:11

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Ag

1995
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
    Harefuah, 1996, Apr-15, Volume: 130, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C

1996
Development of a canine chemotherapeutic model with ifosfamide.
    Laboratory animal science, 1996, Volume: 46, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Blood Platelets; Bone Neoplasms; Dogs; Drug Administrati

1996
Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
    Cancer, 1997, Jan-15, Volume: 79, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant;

1997
Chemotherapeutic induction of long-term remission in metastatic medulloblastoma.
    Journal of neuro-oncology, 1997, Volume: 32, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cerebellar Neoplasms; Cisplat

1997
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D

1997
[The type of local treatment conditions the prognosis in patients with nonmetastatic Ewing's sarcoma of the extremities treated with adjuvant chemotherapy].
    Minerva chirurgica, 1997, Volume: 52, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy, Adjuv

1997
Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen.
    Journal of chemotherapy (Florence, Italy), 1997, Volume: 9, Issue:4

    Topics: Adolescent; Adult; Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti

1997
Treatment of childhood post-irradiation sarcoma of bone in cancer survivors.
    Medical and pediatric oncology, 1997, Volume: 29, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

1997
Miliary osteosarcomatosis with associated hypocalcemia.
    American journal of clinical oncology, 1997, Volume: 20, Issue:5

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antine

1997
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Data Collection; Doxorubicin; Granul

1997
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Sch

1997
Prolonged survival in a nasopharyngeal carcinoma patient with multiple metastases: a case report and review of the literature.
    Japanese journal of clinical oncology, 1997, Volume: 27, Issue:5

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl

1997
The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms;

1997
[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms;

1998
Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma.
    American journal of clinical oncology, 1998, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr

1998
Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study.
    Acta oncologica (Stockholm, Sweden), 1998, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap

1998
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
    International journal of radiation oncology, biology, physics, 1998, Sep-01, Volume: 42, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

1998
Chemotherapy and P-glycoprotein expression in chondrosarcoma.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 1998, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo

1998
Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biot

1998
Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
    Medical and pediatric oncology, 1999, Volume: 32, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

1999
Predictive factors of histological response to primary chemotherapy in Ewing's sarcoma.
    Acta oncologica (Stockholm, Sweden), 1998, Volume: 37, Issue:7-8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

1998
Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
    British journal of cancer, 1999, Volume: 79, Issue:7-8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Drug Administrati

1999
Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study.
    International journal of radiation oncology, biology, physics, 1999, Jun-01, Volume: 44, Issue:3

    Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow

1999
Management of cancer in pregnancy: a case of Ewing's sarcoma of the pelvis in the third trimester.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cesarean Section; Disease-Fre

1999
[A case of metastatic liver tumors from prostatic cancer responding to intra-arterial infusion chemotherapy with CDDP and ifosfamide using implantable port].
    Hinyokika kiyo. Acta urologica Japonica, 1999, Volume: 45, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasm

1999
RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
    Bone marrow transplantation, 1999, Volume: 24, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Bone N

1999
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2000
Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG).
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1999
Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2000
Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    British journal of cancer, 2000, Volume: 82, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Cross

2000
High-dose indium 111In pentetreotide radiotherapy for metastatic atypical carcinoid tumor.
    Southern medical journal, 2000, Volume: 93, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoid Tumor; Cisplatin; E

2000
Long-term survival following extra-neural metastasis from a pineoblastoma.
    Journal of neuro-oncology, 2000, Volume: 48, Issue:2

    Topics: Acetabulum; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neopla

2000
Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-01, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil

2001
Selective use of whole-lung irradiation for patients with Ewing sarcoma family tumors and pulmonary metastases at the time of diagnosis.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2001
Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
    Journal of chemotherapy (Florence, Italy), 2001, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxoru

2001
Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-15, Volume: 19, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj

2001
Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,.
    Clinical orthopaedics and related research, 2001, Issue:386

    Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla

2001
Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases.
    Journal of chemotherapy (Florence, Italy), 2001, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

2001
Painful peripheral neuropathy after treatment with high-dose ifosfamide.
    Medical and pediatric oncology, 2001, Volume: 37, Issue:4

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Combined Modality Therapy; Dose-Respo

2001
Postchemotherapy confusion.
    Oncology nursing forum, 2001, Volume: 28, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Ifosfamide; M

2001
Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.
    Journal of surgical oncology, 2001, Volume: 78, Issue:3

    Topics: Adolescent; Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone

2001
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2002, Volume: 40, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin;

2002
[Treatment of Ewing's sarcoma with 2 different protocols].
    Annales de medecine interne, 2001, Volume: 152, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

2001
Postoperative radiotherapy in the treatment of Ewing tumors: influence of the interval between surgery and radiotherapy.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2002, Volume: 178, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols

2002
Primary treatment of pelvic osteosarcoma. Report of five cases.
    Cancer, 1992, Mar-01, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemot

1992
Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

1992
Ewing's sarcoma: experience with 12 cases.
    Journal of chemotherapy (Florence, Italy), 1992, Volume: 4, Issue:1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

1992
No benefit of ifosfamide in Ewing's sarcoma: a nonrandomized study of the French Society of Pediatric Oncology.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:9

    Topics: Bone Neoplasms; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Ifosfamide; Mal

1992
Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
    Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1992, Volume: 39, Issue:2

    Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Female; Hum

1992
Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping.
    Investigative radiology, 1992, Volume: 27, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant;

1992
A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma.
    Cancer, 1991, Jun-15, Volume: 67, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma,

1991
IIB osteosarcoma. Current management, local control, and survival statistics--São Paulo, Brazil.
    Clinical orthopaedics and related research, 1991, Issue:270

    Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brazil; Cispla

1991
Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities.
    Clinical orthopaedics and related research, 1991, Issue:270

    Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Length

1991
[Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:12

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Drug Admini

1991
[Two cases of Ewing's sarcoma originating from the adult rib].
    Nihon Kyobu Shikkan Gakkai zasshi, 1991, Volume: 29, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality

1991
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:3 Pt 1

    Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia;

1990
Use of MR imaging to assess results of chemotherapy for Ewing sarcoma.
    AJR. American journal of roentgenology, 1990, Volume: 155, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp

1990
[Developments in the treatment of osteosarcoma since 1979. Report of the statistics at the Centre Léon-Bérard].
    Bulletin du cancer, 1990, Volume: 77, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

1990
[Desmoid fibroma of the scapula. Recurrence with pulmonary metastasis].
    Revue de chirurgie orthopedique et reparatrice de l'appareil moteur, 1989, Volume: 75, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dactinomycin; Female; Fibroma

1989
High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasm

1989
[Ifomide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:1

    Topics: Animals; Bone Neoplasms; Carcinoma, Small Cell; Female; Humans; Ifosfamide; Leukemia, Experimental;

1987
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1986, Volume: 40, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Central Nervous System D

1986
[Objective response of desmoid fibroma to chemotherapy].
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1987, Volume: 41, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dactinomycin; Dru

1987
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Drug Evaluation; Femal

1986